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  Summary 
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Summary 
 
The interest in phosphinegold(I) thiolates as an anti-cancer agent developed as a 
result of the previous discovery of cytotoxicity of phosphinegold(I) thiolates. A series of 
thiocarbamate ligands and its corresponding novel phosphinegold(I) thiolate were 
successfully synthesized and characterized. The compounds’ structure was confirmed by 
elemental analysis and X-ray crystallography. 
Biological evaluation of the synthesised thiocarbamate ligands and 
Phosphinegold(I) thiolates were performed on a range of 7 human cancer cell lines and 
normal human fiboblast for cytotoxicity study. A positive biological activity was 
achieved for the Phosphinegold(I) thiolates at high concentration of 20 micromolar. 
Phosphinegold(I) thiolates were found to be more cytotoxic as compared to the 
thiocarbamate ligands at the same concentration, indicating the importance of the 
phosphine gold(I) function of the molecule. Descriptors such as logP, logD, polariability, 
PSA and the refractivity of the gold(I) complexes and its ligands were predicted using a 
computer software, Marvin. The descriptors were used to attempt the study of the 
structure-activity relationship. Although the compounds’ cytotoxicity were observed on 
the range of cancer cell lines but the structure activity relationship of the complexes was 
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1.1 The physical and chemical properties of gold 
Gold is one of the best known precious metals for use as jewellery, a medium of 
monetary exchange and investment. Gold has long been viewed universally as a symbol 
of status, wealth and power. Beyond its economic utility and social association, gold has 
also been applied in the field of medicine since the earliest of times. 1  
This chapter will review the physical and chemical properties of gold in 
connection with its use in therapeutic medicine. The focus of this thesis will be the 
generation of the novel phosphinegold(I) thiolates with potential use as anti-tumour 
agents. 
 
1.1.1 Physical properties of the element 
 
Gold is a dense, soft, shiny, golden yellow metal with the highest malleability and 
ductility among all elements. 2 These properties can be seen from a very high value of the 
bulk modulus and Poison ratio of 220 GPa and 0.44 respectively. One gram of pure gold 
can be flattened into a thin sheet of up to one square meter. 2  
Gold belongs to the transition metal (d-block), period 6, group 11 of the Periodic 
Table. The elements on the same groups are copper, silver and roentgenium. It has the 
atomic number 79, atomic weight of 196.9665 g.mol-1 and atomic volume of 10.2 
cm3.mol-1. Its symbol, Au, derives from its Latin name aurum which means shining 
dawn. 2, 2 Gold has only one naturally occuring and most stable isotope, 197Au, which 
contains 79 protons and 118 neutrons. Many other neutron deficient isotopes have very 
short half-lives except 195Au, which has a half-life of 183 days. It could be prepared by 
bombarding platinum with 22 MeV protons in a cyclotron. However, this particular gold 
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isotope is not widely use because of its high cost and the need for a separation of gold 
from platinum. 2 The neutron-rich isotopes of gold, 198Au, is used in radiotherapy and 
diagnosis. 
As a naturally soft element, the Vicker’s hardness value is only 216 MN m-2, gold 
is normally alloyed with other elements to increase the strength, and hence its 
applications. 4 Jewellery is usually made from an alloy of gold with other elements such 
as nickel, palladium, platinum or copper. Greenish yellow gold is an alloy of gold and 
silver.  Reddish gold colour is generally derived from an alloy of gold and copper. White 
gold is usually the mixture of gold with nickel, palladium or platinum. The gold content 
in gold alloy is measured in carats (k), with pure gold being designated as 24k. In nature, 
gold does not often react with other elements and is known to be highly inert. 
Pure gold solid crystal system is isomeric (face-centred cubic). The half distance 
between the nuclei of neighbouring atoms in solid gold (atomic radius) is 135 pm. A high 
density of 19.3 g.cm-3 at room temperature allows gold to be extracted from residual 
rocks. Its melting point and boiling point are 1064 oC and 2860 oC correspondingly. The 
heat of fusion is observed at 12.5 kJ.mol-1 and the heat of vaporisation is 334.4 kJ.mol-1. 
In the gas phase, gold also exists as diatomic species, the bond energy (dissociation 
energy) of Au-Au is 226 ± 2 kJmol-1 5 and the Au-Au bond length is measured to be 
around 230-480 pm, depending on methods and conditions during measurement. 6, 7 
Gold exhibits a large relativistic effect as compared to other elements from the 
same group such as silver. 8 This effect can be used to explain a few common phenomena 
of gold such as its colour, the higher electron affinity and first ionisation energy. 9- 11 Gold 
has the electron affinity of 2.54 while silver has the value of 1.73 (Pauling scale). The 
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first ionisation energies of gold and silver are 890 and 731 kJmol-1 respectively. 
Furthermore, in the solid state, gold exhibits the aurophilicity phenomenon, where gold 
complexes tend to form an interaction of weak Au···Au bond. This particular bond length 
measures about 300-350 pm and is comparable to bond strength of diatomic states in gas 
phase. 12- 14 However it is slightly shorter than the sum of the Van der Waals radius of gold 
at 166 pm. This aurophilicity bond has an energy of stabilisation of about 29-50 kJ.mol-1 
which is of the similar magnitude as hydrogen-bonding interactions. The aurophilicity 
interaction is probably a result of the electron correlation of the closed shell components 
and some of the relativistic effects. 15 
Even though gold has lower specific (electrical) conductivity (45.2 * 106 S.m-1) as 
compared to silver and copper (63.01 * 106 S.m-1 and 59.6 *106 S.m-1 respectively), gold 
is still being used in electronic applications as it is better off in the resistant of oxidation 
and corrosion. In a similar manner, gold also offers lower thermal conductivity (320 
Wm1K-1) as compared to silver and copper (430 Wm-1K-1 and 401 Wm-1K-1) 
respectively. 2 
Gold exhibits the refractivity of 95% of the light at 1000 nm wavelength and a 
speed of sound of 2030 m·s−1. Table 1 represents the comparative properties of gold and 
some similarly grouped elements in the group 3. 
Table 1 Comparative properties of Gold and some similarly grouped elements 
in the group 3 
 
 
Properties / Elements 
 
Cu Ag Au 
Element category 
 
Transition metals Transition metals Transition metals 
Group, Period, Block 
 
11, 4, d 11, 5, d 11, 6, d 
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Properties / Elements 
 
Cu Ag Au 
Appearance Metallic bronze Silver Metallic yellow
 
Standard atomic weight, 
(g·mol−1) 
63.546 107.868 196.966 
Electron configuration [Ar] 3d10 4s1 [Kr] 4d10 5s1 [Xe] 4f14 5d10 6s1 
Electrons per shell 2, 8, 18, 1 2, 8, 18, 18, 1 2, 8, 18, 32, 18, 1 
Phase Solid Solid Solid 
Density (room 
temperature), (g·cm−3) 
8.96 10.49 19.3  
Liquid density at m.p, 
(g·cm−3) 
8.02 9.3 17.3   






Boiling point (K, °C,  °F) 2835, 2562, 4643 2435  2162, 3924 3129, 2856, 5173 
Heat of fusion, (kJ·mol−1) 13.26 11.28   12.55   
Heat of vaporization, 
(kJ·mol−1) 
300.4 250.58 324   
Specific heat capacity, (25
 °C), (J·mol−1·K−1) 







Cubic face - 
centered 
Oxidation states +1, +2, +3, +4
(mildly basic 
1, 2, 3 
(amphoteric 
−1, 1, 2, 3, 4, 5
(amphoteric 
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Properties / Elements 
 
Cu Ag Au 
oxide) oxide) oxide) 
Elements / Properties 
 














1st: 890.1  
2nd: 1980  
Atomic radius, (pm) 
 
128 160 135 
Atomic radius (calc.), (pm) 
 
145 165 174 
Covalent radius, (pm) 
 
138 153 144 
Van der Waals radius, (pm)
 
140 172 166 
Magnetic ordering 
 













16.5 18.9 14.2  
Speed of sound (thin rod), 
(m·s−1) 
3810 2680 2030   
Young's modulus, (GPa) 
 
110 - 128 83 78   
Shear modulus, (GPa) 
 
48 30 27   
Bulk modulus, (GPa) 
 
140 100 180   
Vicker’s Hardness, (MPa) 
 
369 251 216 
Poisson ratio 
 
0.34 0.37 0.44 
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1.1.2 Chemical reactivity of the element 
 
Gold is very stable in nature as it is the only metal inert to moisture, oxygen and 
sulphur under any temperature. 4 It does not react with any aqueous bases. However, gold 
readily reacts with all halogens such as bromine, chlorine, and iodine to form Au2Br6, 
Au2Cl6 and AuI respectively. It also dissolves rapidly in a mixture of hydrochloric acid 
and an oxidising agent such as nitric acid (aqua regia). In a similar manner, gold 
dissolves in hydrochloric acid in the presence of the oxidants hypochlorite or Fe(III).2  
Also, gold dissolves in cyanide solution with air or hydrogen peroxide as oxidant. 4 
Atomic gold is believed to be more reactive as compared to the gold metal. The study 
demonstrated that the complexes of mono (dioxygen) gold and the gold carbocanyls can 
be prepared even at temperature of 10K. 16  
1.1.3 Coordination chemistry of gold and gold complexes 
 
Elemental gold processes the electronic configuration [Xe]4f145d106s1. It does not 
have any closed shell-electrons and hence is considered a most noble metal. In gold 
complexes, the known oxidation states ranges from -I to V. 17 However, oxidation states I 
and III received the most interest in recent years as many such studies are undergoing 
biological evaluations. Gold(I) complexes were shown to have some therapeutic effect. 
Moreover most gold drugs were found to be in this oxidation state. In the past, gold(II) 
was only shown to be present in the intermediate form in biological reactions. Gold(III) 
have been found to be rather toxic. Gold(IV) and gold(V) do not have any role in 
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biochemical processes. Complexes derived from important oxidation states 0, I, II, III and 
V of gold are summarised below.  
 
 
Oxidation State 0 
Gold nanoparticle has gained substantial interests in recent years and wide 
applications in biology and medicine are being explored, e.g potential for noninvasive 
and early diagnostics and treatment of cancer. 18 
Oxidation State I 
While Gold(I) is generally more thermodynamically stable complexes as 
compared to gold(III), it is not stable in aqueous solutions. 4 Without any stabilising 
ligands, Au(I) will disproportionate as described in the equation below: 
                         3Au(I) (aq) →  2Au (s) +  Au(III) (aq)             Eө =  +0.47 V 
As Au is a soft centre metal, the preferred stabilising ligands are generally soft, π 
accepter ligands such as CN-, PR3, RS-, R2S, RN-, Cl-, RCO2-. 19 Close shell state Au(I) 
(with [Xe]4f145d10 electron configuration) are usually diamagnetic, forming two-
coordinate complexes rather than three or four coordination like Ag(I) and Cu(I). The 
complexes are known to have a linear (rod-like) geometry with weak additional bond 
(aurophillic) in solid state. Typically, aurophillic bonding between the gold atoms in the 
linear coordination make them align in opposite direction in a long zigzag, parallel in a 
head to tail or head to head fashion to form chain or sheet (Figure 1). The Au...Au bond 
length was reported around 350 pm. 11 The strength of bonding is estimated at between 
25-40 kJmol-1 and it can be increased when preferred ligands such as thiolates were used. 
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The aurophillic property of gold sparks a lot of interests in the field of crystal 
engineering.  20 
The relativistic effects of gold allow the stabilization of the 6s orbital which 
reduces the energy gap between this 6S and the 5d orbitals. At the same time the 5d 
orbitals also undergoes an expansion. Therefore, the small difference of energy among 
the s, p, or d orbital affords the efficient formation of s/d or s/p hybridizations, resulting 
in gold(I) being linear two-coordinate complexes. The probability to form two 
coordination complexes is much greater than other isoelectronic centers, such as 
platinum(0), silver(I), or mercury(II). They are usually found to have compounds in 
higher coordination numbers. 
The linear geometry of the two coordinate complexes can be explained by the 
valence-shell electron repulsion theory (VSEPR) theory which was developed by 
Gillespie and Nyholm.  21 Two coordinated gold complexes can be found in the form of 

















     (1) 
Figure 1 Examples of gold (I) complexes [C3H7NCAuCl] with linear geometry 
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The majority of gold compounds in the oxidation state I are two-coordinate, with 
linear geometry. However, other complexes with, higher coordinate complexes have also 
been characterized (Figure 2). They are usually three-coordinate trigonal-planar and 
tetrahedral four-coordinate complexes. In the past these compounds were not common, 
however, a rapid expansion of study in this field has taken place especially after the 























    (2)     (3) 
Figure 2  Examples of gold (I) complexes with higher coordinate 
complexes  (2) - [(TPA)3Au)2Au2(S2C2(CN)2)2]   (3) - [Au(S2CPh)(PPh3)2] 
 
Oxidation State II 
Au(II) and its complexes are of special interest for the gold coordination 
chemistry. However its compounds are very rare as compared to Au(I) and Au(III). In the 
past, Au(II) species were reported to exist only as short living intermediates in redox 
reactions between the Au(I) and Au(III). 25 Some of the complexes generated in this 
oxidation state were reported to be unstable. 26 
Presently, a number of stable dinuclear and polynuclear gold(II) complexes have 
been characterised (Figure 3). The stability of the complexes very much depends on its 
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ligands. In general, gold(II) compounds (with [Xe]4f145d9 electron configuration) are 

























(4)    (5) 
Figure 3 Structures of di and tri nuclear gold (II) complexes with a gold-gold 
bond - a) binuclear complex, b) trinuclear complex 
 
 
Unsaturated sulphur-containing ligands such as dithiolate and dithiocarbamate are 
reported to stabilize Au(II) to form monomeric four coordinated square-planar complexes 
(Figure 4). Electron delocalization through the ligand π-system is responsible for the 














      (6) 
Figure 4 Structure of a square planar four coordinate gold(II) centre,27 
 [AuII(dmit)2]2-  
 
Recently a stable monomeric hematoporphyrin Au(II) complex has been 
synthesized and characterised (Figure 5). The formula and structure of the complex have 
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been reported. Au(II) species are stabilized via coordination of the four nitrogen atoms of 


















      (7) 
Figure 5 Structure of a Octahedral coordinate gold(II) centre, [Au-(II)Hp-
2H.(H2O)2] 
 
Oxidation State III 
Gold(III) is isoelectronic with Pt(II) and Rh(I). Having the same electronic 
configuration with Pt(II), its complexes are also known to be diamagnetic and favour 
similar four-coordinated, square-planar geometry. Au(III) can be reduced rapidly by 
thiols and sulfides to Au(I) compounds. 
 Higher coordinated gold(III) complexes have also been reported, for example 
AuCl3(2,2’-biquinolyl) with square pyramidal or distorted square pyramidal (Figure 6) 
and [AuCl3(2,9-dimethyl-1,10-phenanthroline)] with rigid bidentate nitrogen-donor 
ligands. 29 Trigonal pyramidal gold(III) complexes were reported to exist as an 
intermediate during ligand-substitution reactions in square planar gold(III) complexes.  30 
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     (8) 
Figure 6 Structure of square pyramidal coordinate gold(III) centre, 
[AuCl(CllH8N30)2].H20]. 
 
Oxidation State V 
 Gold fluoride (AuF5)2 is the example of higher oxidation state gold complex 
reported. In solid state, (AuF5)2 is the only dimeric structure of pentafluoride found; other 
pentafluorides are monomeric. It is a diamagnetic hexacoordinated gold and octahedral 
structure with a 5d6 electronic configuration. 32 This compound is known to be a very 
powerful oxidising agent and so far no biological studies have ever been carried out on 
the compound with this oxidation state. 
                   
1.2 Medicinal Chemistry of Gold Compounds 
1.2.1 Historical use of gold in medicine 
 
Gold element and gold compounds have been used as medicine since ancient 
times. The Arabs, Indians and Chinese have explored the use of gold for medical purpose 
since 2500 BC. In medieval Europe, alchemists had several formulae to make an elixir 
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called aurum potabile, which usually contained small flakes or powder of gold. In the 
17th century, gold cordial was used in the treatment of ailments caused by a decrease in 
vital spirits such as fainting, fever and falling ill. 33 However, the modern use of gold 
compounds in medicine is best attributed to Chrestien and Figuier who introduced gold 
sodium chloride for the treatment of syphilis in the early 19th century. 34  
In 1890 the German bacteriologist and nobel laureate Robert Koch discovered the 
anti-bacterial property of gold cyanide towards the tubercle bacillus. 35 Subsequently, gold 
therapy for tuberculosis was introduced in the 1920s. The belief that the tubercle bacillus 
was also a root cause for rheumatoid arthritis led to the advocacy of gold therapy for this 
disease. 36 However, gold therapy was later proved to be ineffective for tuberculosis but a 
breakthrough for the treatment of rheumatoid arthritis was realised. The term 
‘Chrysotherapy’ refers to the treatment of rheumatoid arthritis with gold(I) thiolates. 37   
1.2.2 Gold complexes in the treatment of rheumatoid arthritis (RA) 
 
Gold has been use in the treatment of rheumatoid arthritis for the past 70 years. 
There are several first generation complexes used clinically in the treatment of severe 
cases of rheumatoid arthritis which included aurothioglucose (Solganol®) (9), di-sodium 
aurothiomalate (Myocrisin®) (10), tri-sodium salt of bis(thiosulfato)gold (Sanocrysin®) 
(11),    aurothiopropanol   sulphonate (Allocrysin®)  (12),   gold(I) 4-amino-2-
mercaptobenzoate (Krysolgan®) (13). Most of these, except tri-sodium of 
bis(thiosulfato)gold (3), are polymeric complexes with linear gold(I) ions, thiolate-
bridging, and a gold:ligand ratio of about 1:1. The chemical structures are shown in 
Figure 7.  1,  38 These structures with thiolate-bridging and linear gold(I) ions were 
elucidated by the X-ray techniques of WAXS (Wide Angle X-ray Scattering) and EXAFS 
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(Extended X-ray Absorption Fine Scattering). 39- 41 However, the precise structures of 
these polymers are not known.  
The second-generation drug for the treatment of rheumatoid arthritis was 
introduced as an orally active gold drug in 1985. Auranofin [tetra-O-acetyl-β-D-
(glucopyranosyl)thio]-(triethylphosphine)gold(I) Ridaura®, (14) is shown in Figure 7. 42 
The X-ray crystallographically determined structure revealed it to feature a linear P-Au-S 
geometry. 38 As it is lipophillic in nature, this drug can be administered orally in a small 
dose of approximately 3-6 mg per day. The key role of the phosphine ligand in Auranofin 
is believed to enhance the lipid solubility of the drug so that it can be absorbed in the gut. 
The difference in the solubility profile not only results in a different mode of 
administering the drug, but also in the bio-distribution of the gold throughout the body. 
Therefore, it is expected that the accumulation of gold in the kidney is lesser for 
Auranofin as compared with the first generation drugs. 
1.2.2.1 Pharmacokinetic of gold compounds 
 
As mentioned above, the definite structures for most of the injectable gold 
compounds were not available. Thus, pharmacokinetic profilings are largely centred on 
the measurement of the elemental Au. The prediction of drug activity from Au(I) 
polymeric complex is not very accurate. These drugs are water-soluble, and high doses of 
approximately 50 mg per week is generally administered. 42,  44 Owing to the hydrophilic 
property of the drug, it is directly absorbed into the blood stream. The peak serum Au(I) 
levels of 700–1,000 µg% are achieved 2–6 hours after injection. The level drops to 
around 300 µg% by the 6th day. More than 95 % of the administered gold would react 
with blood protein, albumin, and the remainder is bound to the macroglobulins. 36 As a 
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high percentage of the gold, 75%, is excreted via the kidney and the remainder in the 

































(13) (14)  
Figure 7 Chemical structures for aurothioglucose (9), di-sodium 
aurothiomalate (10), tri-sodium salt of bis(thiosulfato)gold (11), aurothiopropanol 
sulphonate (12), gold(I) 4-amino-2-mercaptobenzoate (13) and [tetra-O-acetyl-β-D-
(glucopyranosyl)thio]- (triethylphosphinegold) 
 
Gold from the compound administered is distributed throughout the immune 
system (reticulo-endothelial) including phagocytic cells located in the reticular 
connective tissue, lymph nodes, spleen and liver. Some patients also experienced the 
deposition of gold in the skin and there have been studies showing the correlation 
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between the amount of gold in the skin and the dosage administered. Moreover, some 
gold has been detected in the milk of the breast feeding mother and gold was also 
transferred to the infant.  36 
Similar to injectable gold, Auranofin also binds predominantly to albumin. Up to 
25% of gold is detected in plasma after oral administration. A little amount of gold in 
plasma was reported after 180 days of oral administration as compared to injectable gold 
compound. It is clinically suggested that Auranofin is somewhat less effective than the 
injectable gold complexes. 
1.2.2.2 Mechanism of action of gold complexes 
 
Despite almost 70 years of clinical use of gold complexes, its mechanism of action 
is not well understood. Many mechanisms were proposed over the years. A few 
mechanisms are summarized below. 
 
A. Cyanide metabolites 
It is not surprising that aurocyanide [Au(CN)2]- is well known as a metabolite of 
gold compounds. This proposal received considerable attention as it is a common 
metabolites in most gold drug used clinically. It targets certain immune cells involved in 
the inflammatory responses. 45 Researchers found out that [Au(CN)2]- is generated by 
stimulated polymorphonuclear leukocytes and thiocyanate, SCN-, is a possible substrate 
by the action of myleoperoxidase. At the sites of inflammation, hydrogen peroxide 
(H2O2) and myeloperoxide (MPO), the peroxide-consuming enzymes were produced. 
Thus, CN- can be generated from the reaction between SCN- and H2O2/MPO.  Similar 
reactions of iminoacids, products of D-aminoacid oxidase, can also produce CN-.56 
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Because of the strong affinity of cyanide for gold(I), it can react with gold to form 
[Au(CN)2]-. Researchers found out that [Au(CN)2]- can be bound to albumin in the blood 
serum and it can also be reversed. 46- 48 The understanding of [Au(CN)2]- roles might allow 
the key step for understanding the mechanism of action of gold drugs on the inflamed 
joints and immune systems of the RA patients.  
 
B. Oxidation of gold (I) to gold (III) in Vivo 
The correlation between therapeutic benefit and T-cells reactive to gold(III) was 
observed and this mechanism was then suggested. The studies showed that gold(I) drug 
can be activated in vivo to gold(III) metabolites that are responsible for some side effects 
in the treatment of gold. 49 The studies demonstrated that T cells from chrysotherapy 
patients were sensitized against gold(III) but not gold(I). The findings were substantiated 
by the possible oxidation of gold(I) thiolate  to gold (III) by hypochlorous acid generated 
by the enzyme myeloperoxidase during the oxidative burst at inflamed sites. 45 Recently, 
De Wall et al, has shown that gold(III) from KAu(III)Cl4 is  able to remove antigenic 
peptides from major histocompatibility (MHC) class II molecules, thus inhibiting the 
activation of the self-reactive T lymphocytes that caused rheumatoid arthritis or other 
autoimmune diseases. This finding may lead to the mechanism of gold(I). 50,  51 
 
C. Ligand Displacement 
Biological evaluations in humans and laboratory animals demonstrated that the 
gold drugs used clinically are considered as pro-drugs, whose original compounds  are 
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rapidly undergoing chemical conversion, by metabolic processes, yielding an active 
pharmacological species. 45 
The gold compounds used to treat arthritis are all linear, 2-coordinate gold(I) 
thiolates. As mentioned above, gold(I) and gold(III) are not stable in aqueous and has the 
tendency to be reduced by mild reducing agent. However, the cyanide or thiolate ligand, 
stabilises the gold(I) to prevent the disproportionation to gold(0) and gold(III) whilst still 
permiting exchange reactions with biological ligands. 45  
Albumin is the major protein in serum and is the major source of biological thiols. 
It is believed that the displacement of the thiolate ligand with albumin occurred at the 
cysteine-34 sites. The thiol group in the drug was displaced by the protein. Subsequent 
reaction of gold compounds with other thiols such as albumin or glutathione took place. 
In the case of Auranofin, the liberated triethylphosphine (Et3P) is oxidised to harmless 
triethylphosphine oxide, which is excreted via the kidneys (Figure 8).  52 Studies showed 
that gold and its carrier ligands have different distribution and excretion times, where 
gold retained in various organs more effectively than the thiolate ligands. Moreover, low 
concentrations of thiomalate was detected in patients who had taken myocrysine and 
Au(CN)2- was detected as a common metabolites. These findings strengthened the 
significance of ligand displacement reactions in human. It is clearly seen that gold 
compounds serve as a carrier to deliver gold to form gold-protein complex to allow 
therapeutic advantage of gold. 38 
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1/n(Au-SR)n   +   2Alb-SH Alb-S-Au-SR Alb-S-Au-S-Alb   +   2RSH















Alb  + Et3P=O
 
Figure 8 Metabolic Pathway of gold drugs 
 
D. The thiol-shuttle model  
Injectable gold drugs like aurothioglucose (1) and disodium aurothiomalate (2), 
are injected intramuscularly in to the blood stream as they are usually water-soluble. The 
drugs do not enter cells but, rather, bind to the cell surface thiols and interact with cells. 
However, Auranofin (6) is hydrophillic and believed to have a different mechanism of 
transportation of gold in and out of cells i.e. the drugs are taken up rapidly by cells. 
Mirabelli et al. postulated a thiol-shuttle (or sulfhydryl-shuttle, Figure 9) to explain the 
behaviour of Auranofin. 53 
It was proposed that Sulfhydryl-dependent membrane protein (MSH) provided a 
vehicle for the movement of Et3PAu+ across the membrane where Et3PAu+ moiety binds 
to the MSH. While the gold ion is inside the cell, the ion can be displaced by the proteins 
and low-molecular-weight sulfhydryls resulting in the oxidation of phosphine to Et3PO. 
In red blood cells, the gold can also bind to glutathione and haemoglobin. 54 
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AlbSAuPEt3 AlbSAuSC  
Figure 9 Thiol-shuttle Model (CSH refers to cytosolic thiols, protein or low 
molecular weight thiols) 
1.2.2.3 Clinical Treatment with gold compound for RA patients 
 
From the 1970s till present, gold complexes are only recommended for the 
treatment of RA as the last line of defence once it had been established that the disease 
symptoms were not responsive to adequate treatment with non-steroidal anti-
inflammatory agents. The patients were usually strictly monitored. Also, injectable and 
oral gold therapy for children with arthritis should be under the supervision of a physician 
with in-depth knowledge of paediatrics and gold therapy. It has been found that injectable 
gold sodium thiomalate is a better clinical choice than Auranofin as it provides greater 
effectiveness and a relatively better side effect profile in the rheumatoid arthritis patient. 
1.2.2.4 Adverse effect of gold compound 
 
Adverse reactions are the major limiting factor to the use of injectable gold 
compounds. Some side-effects of anti-arthritic therapy using gold(I) occur, especially 
when it is oxidised to toxic gold(III) by some of the potentially strong oxidants such as 
hydrogen peroxide available in-vivo during inflammatory situations. Gold(III) can then 
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oxidise disulphide bridges in albumin and insulin. Also, a metabolite of chrysotherapy is 
[Au(CN)2]- which can be taken up by red blood cells and affects the function of other 
cells.  52,  54 
As mentioned earlier, the major side effect of using gold(I) drugs is 
nephrotoxicity. Other adverse side-effects include a metallic taste in the mouth, oral 
ulcer, discolouration of the skin, dermatitis, diarrhoea, nausea, flushing, vomiting, bone 
marrow damage, skin reactions, pulmonary injury, blood disorders and occasional liver 
toxicity. 36 Despite all the negative effects, the patients are still using gold drug to 
alleviate the symptoms because there is apparently no cure for rheumatoid arthritis. Gold 
drugs are generally prescribed as a last resort to alleviate the symptoms associated with 
rheumatoid arthritis. 37 
1.2.3 Gold complexes in other potential clinical application 
 
Despite the use of gold in the treatment of rheumatoid arthritis, the development 
of gold complexes to target anti-microbial activity, malaria, treatment of bronchial 
asthma, AIDS, are on-going and command considerable interests.  
 
1.2.3.1 Antimicrobial activity 
Robert Koch first demonstrated that gold compounds have anti-microbial effect 
against the tubercle bacillus. Recent work by Fricker and co-workers has shown that 
gold(I) and gold(III) compounds have the anti-microbial activity against Gram-positive 
bacteria. A gold(I) thiocyanate complex [Au(SCN)(PMe3)] demonstrated activity against 
Gram-positive bacteria including MRSA. 33 It was also found that gold(I) phosphonium 
dithiocarboxylato complexes demonstrated activity against ‘problem Gram positive 
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cocci’. Gold(III)-thiosalicylate (15) and -salicylate (16) complexes (Figure 10) with 
moderate antimicrobial activity against a range of bacteria and fungi have been 
reported. 55 P. Ghosh and co-workers recently found that a gold complex, [1-benzyl-3-tert-
butylimidazol-2-ylidene]AuCl, (17) exhibited significant antimicrobial properties. 56 
Interestingly, the presence of gold nano particles in methylene blue was found to 
significantly enhance the ability of methylene blue to kill bacteria methicillin-resistant 






















Figure 10 Chemical structures of gold(III) salicylate complex (15), gold(III) 
thiosalicylate complex (16) and 2-benzylpyridylgold(III) catecholate (17) 
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1.2.3.2 Anti-malaria 
Anti-malarial drugs were found to exhibit similar pharmacological profiles to that 
of gold drugs, indicating that similar features exist between the mechanism of action of 
the anti-malaria and anti-arthritic drugs. 34 The gold–chloroquine complex 
[Ph3PAu(chloroquine)]PF6 (18), (Figure 11) is active in vitro and in vivo on P. berghei 
and P. falparum, the gold moiety providing an important increase in chloroquine 
efficiency. 58  These two strains are known to initially resist Chloroquine®. Moreover the 
presence of the phosphinegold(I) moiety in metal chloroquine complexes also resulted in 
an enhancement of growth inhibitory activity on the Trypanosoma cruzi, the root cause 
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1.2.3.3 Asthma 
Patients with chronic severe asthma are often dependent on the long term 
prescription of oral corticosteroids. Physicians are still searching for alternative therapies 
that can reduce the need for oral steroids. Gold compounds, the immunosuppressive 
agents with known benefits in the treatment of inflammatory disorders, have been 
identified as potentially useful agents in the treatment of chronic severe asthma. 
Auranofin was found to provide an effective addition to the treatment of steroid 
dependent asthma, leading to a reduction of oral steroid dose. Meanwhile, another study 
showed that the theophylline administered concurrently with methylprednisolone (steroid 
compound) and auranofin suggested a possible interaction between theophylline and 
auranofin. 61 Some significant side effects associated with the use of gold complex were 
also reported, thus further evaluation in this area is warranted. 
 
1.2.3.4 Anti HIV and AIDS 
An AIDS patient who was treated with Auranofin for psoriatic arthritis was found 
to have increasing CD4+ T cell counts. In general, CD4+ T cell counts would decline for 
a patient with the human immunodeficiency virus (HIV) virus. This incident has led to 
the investigation of a variety of gold compounds against HIV in vitro.62 Dicyanogold was 
found to inhibit the replication of the HIV virus in a cell culture model and may have the 
potential in treating AIDS in combinations with other drugs. 63  
However, so far there is very limited success on the use of gold compounds as an 
antiviral agent. Recently, there were numerous interests in using gold nanoparticles to 
enhance the biological activity in the treatment for HIV.  64 
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1.3 Pharmacological potential of gold complexes 
 
Although gold complexes are used currently in the clinical treatment of RA, there 
are numerous efforts dedicated in developing anti-tumour agents of both Au(I) and 
Au(III).  
1.3.1 Cancer 
Cancer occurs when abnormal cells divide without control and invade other 
tissues. Cells with damaged DNA cannot repair themselves and can spread to other parts 
of the body through the blood and lymph systems via a process known as metastasis. 
There are more than 100 different types of cancer with names normally derived from the 
organ in which the cancer starts. Most cancers are in tumour form, but some like 
leukemia do not have tumour. Cancer can be treated by different methods depending on 
the location, grade of the tumour, the stage of the disease and the state of the patient. 
Chemotherapy is one of the methods normally employed as a therapy of the disesase. It 
refers to the treatment of disease by chemicals that kill micro-organisms or cancer cells.  
1.3.2 Gold complexes in the treatment of cancer 
 Investigations on the anti-tumour activity of gold drugs were based on a few 
reasons. First, the analogies of square planar complexes of Pt(II) and Au(III). Gold(III) 
complexes are isostructural and isoelectronic to platinum(II) complexes. It is obvious that 
cisplatin is the most widely used anti-cancer drug particularly for head and neck, ovarian 
and testicular cancer. 37 It adopts the same square planar structures with Au(III), 
indicating perhaps that Au(III) complexes may also exhibit anti-cancer properties as does 
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cisplatin. Secondly, the analogy of the immunomodulatory effect of gold(I) anti-arthritic 
agent.  Studies, showing that patients undergoing chrysotherapy have reduced risk from 
suffering from cancer, suggest possible links between the two symptoms. Moreover, 
drugs used clinically such as cyclophosphamide, 6-mercaptopurine and methotrexate are 
known to have both immonosuppressive and anti-inflammatory activities. 65, 66 Last but not 
least, biological evaluation of gold(I) and gold(III) compounds showed anti-tumour 
properties. The discovery that Auranofin had an activity against HeLa in vitro and P388 
in vivo, led to extensive screening of many Auranofin analogues on various cell lines. 67, 68 
The limited but useful information about the mechanism of gold(I) drug was also built 
into the consideration for evaluating Auranofin in the anti-tumour activity. The 
hydrophilic property of Auranofin offered some confidence regarding the 
pharmacokinetic of the compound. The trials on auranofin molecules sparked interests in 
other phosphine gold(I) thiolates.  
Despite numerous researches on gold compounds for anti-tumour activity, no gold 
compound has yet entered clinical trials for the treatment of cancer. 37 
 
1.3.2.1 Anti-tumour activity of gold(I) compounds 
1. Tetahedral gold(I) compounds 
Studies showed that bidentate phosphines Au(I) complexes of 
bis(diphenylphosphino)ethane (dppe) rearranged in solution to form the bis-chelated, 
tetrahedrally coordinated Au(I) species, [Au(dppe)2]+ (19), (Figure 12). These 
compounds presented exciting cytotoxicity profiles. 69 Recently, tetrahedral 
gold(I)complexes of bidentate pyridyl phosphines have shown promising in vitro and in 
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vivo antitumour properties against cisplatin-resistant human cancer cells  that are 
determined by their drug lipophilicity. 70 Berners et al, showed that the lipophilic, 
cationic, bis-chelated 1:2 Au(I) diphosphine [Au(dppe)2]+ exhibits anti-tumour activity 
against a range of tumour models in mice. The study on the combination of cisplatin with 






Figure 12 Chemical structure of cationic [Au(dppe)2]+ (19) 
 
 
Observations showed that the most active complexes had phosphorus-bound 
phenyl groups, i.e. [Au(dppe)2]+. It was suggested that the reduced potency of complexes 
with phosphorus-bound ethyl substituent could be correlated to the ability to be oxidised 
to phosphineoxides. 72 A three coordinated analog of phosphine ligands (20), (Figure 13) 
demonstrated potency against the breast tumour MCF-7. 73 A novel hydrophilic gold 
compound, tetrakis((trishydroxymethyl) phosphine)gold(I) chloride (21), (Figure 13)  had 
been investigated for its anti-tumour properties for both in vitro and in vivo. 75  
Despite the encouraging in vitro and in vivo results, there were no clinical trials 
for this gold complex [Au(dppe)2]+ species due to its associated toxicity. In the 
preclinical toxicity studies, the compound exhibited toxicity in the liver, the heart, and in 
the pulmonary vasculature in the Beagle dogs studied. The compound was also 
cardiotoxic in rabbits. It is believed that the complex [Au(dppe)2]+ caused the interruption 
of mitochondrial function and altered mitochondrial calcium homeostasis, which is a 
contributing factor leading to cardiac myofibril necrosis. 75 
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Figure 13 Chemical structures of gold complexes Chlorotriphenylphosphine-1,3-
bis(diphenylphosphino)propanegold(I) (20) and Chlorotetrakis((trishydroxymethyl) 
phosphine)gold(I) (21) 
 
Due to the toxicity profile of gold (I) complexes mentioned above, it is possible to 
eliminate or reduce the toxicity and achieve selectivity for tumour cells over normal cells 
by fine-tuning the hydrophilic/hydrophobic balance of these types of compounds. It is 
known that phosphine gold complexes inhibit the growth of cultured tumour cells in vitro 
and many have antimitochondrial activity. Mitochondria are believed to play a vital role 
in the regulation of programmed cell death (apoptosis) and consequently, in diseases 
characterised by abnormal apoptotic responses such as cancer. Auranofin, in the presence 
of calcium ions, is a highly efficient inducer of mitochondrial membrane permeability 
transition, potentially referable to its inhibition of mitochondrial thioredoxin reductase. 
Previous knowledge showed that optimization of the compounds’ hydrophilic/lipophilic 
balance is the key to improving the selectivity for tumour mitochondria versus oxidative 
phosphorylation pathways of normal cells. 76-  78 This concept allowed the design of the 
gold complex with certain solubility to target mitochondria. N-heterocyclic carbene 
(NHC) ligands were explored as alternatives to phosphines moiety in the gold complex. 
Recently, gold(I) complexes of bidentate N-heterocyclic carbene ligands, (22), were 
synthesized and characterized. 79 Example of the gold(I) complex is shown in Figure 14. 
The designed compound was evaluated for its ability to induce mitochondrial membrane 
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permeabilisation. 80 The direct relationship between the anti-mitochondrial activity and 
the lipophilicity of the complex had been established. It was also assumed that these 
lipophilic cationic Au(I)–carbenes have a different mechanism of antimitochondrial 
activity to [Au(dppe)2]+ and pyridylphosphine analogs which are also Au(I) lipophilic 
cations. The differences might be due to the fact that these phosphine compounds are 
unreactive towards thiols complexes. 81 In addition, the luminescence characteristic of this 
particular range of compounds was also being explored to monitor the gold carbine in the 
cells which might allow a better understanding of the mechanism of actions. 82 More gold-
based lipophilic cations were also being explored for mitochondrial-interactive anti-

















Figure 14 Example of Chemical structures of gold-carbine complexes (22) 
 
 
2. Auranofin Analogs 
Large number of gold(I) complexes especially Auranofin analogs have been 
evaluated for anti-tumour activity. This could be attributed by the known fact that 
Auranofin and its analog possess some anti-tumour activity and is prodrug. Generally, 
 Chapter 1                                                                                                                                        Introduction  
Phosphinegold(I) Thiolates: Synthesis and Biological Activities 31
phosphinegold(I) thiolates were found to be more cytotoxic than gold thiolates and 
phosphinegold(I) chloride analogues. Gold(I) thiolate complexes such as solgano and 
myocrisin have been tested for anticancer activity but were found to be inactive.  84,  85 This 
emphasized the importance of the phosphine ligand and the thiolate for biological 
activity, and the investigation of Auranofin analogues still continues. These observations 
have led to some design of gold complexes with the aim to find anti-cancer activity. The 
cytotoxicity activity observed in Auranofin, might have been the result of the liberated 
thiol after the metabolisation of phosphinegold(I) thiolate in the human body. If this 
being the case, coupling the biologically active thiols with phosphinegold(I) entity would 
provide biological effect. 86 Following this idea, thiols such as 6-mercaptopurine was 
coupled with phosphinegold(I) against leukaemia cell lines. The IC50 value showed an 
increased benefit of Ph3PAu(6-MP). In vivo results indicated that gold compound 
inhibited the tumour growth significantly. However, there was no structure-activity 
relationship present in the compound investigated. Series of gold(I) dithiocarbamate 
compounds and derivatives were further investigated for their cytotoxicity. De Vos et al, 
reported that Et3PAu(S2CNEt2) was found to be more active than cisplatin against ovarian 
cancer cell lines. 87 Mononuclear dithiocarbamate ester and dinuclear gold(I) complexes 
displayed little cytotoxicity in the investigated cell lines. 88 Furthermore, a class of tertiary 
phosphinegold(I) complexes with thiosugar ligands [Au(SR)(PEt3)] are extremely 
cytotoxic and active against both the P388 leukaemia and B16 melanoma in vitro and 
P388 in vivo.  89  Vitamin K3 derivatives were also tested and found to be active against a 
few cancer cell lines. 89 Examples of the Auranofin analogs were presented in Figure 15, 
(23), (24) and (25). 
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Figure 15 Chemical structures of gold (I) complexes Ph3PAu(6-MP) (23), 
Et3PAu(S2CNEt2) (24) and Vitamin K derivatives (25) 
 
1.3.2.2 Anti-tumour activitiy of gold(II) compounds 
 In the past, a proper cytotoxic gold(II) complexes are rather scarce due to their 
redox stability and kinetic behaviour. Nowadays, the Au(II) oxidation state can be 
considered a common state in gold chemistry. Recently, a stable distorted octahedral 
structure of monomeric hematoporphyrin Au(II) complex  has been reported. The 
compound was also investigated in a panel of tumour cell lines. The complex exhibited 
strong cytotoxicity on the leukaemia- and lymphoma-derived cell lines. 28  Figure 16 
showed the structure of [Au-(II)Hp-2H.(H2O)2] 
 
1.3.2.3 Anti-tumour activitiy of gold(III) compounds 
As mentioned above, gold (III) complex is isoelectronic with cisplatin, containing 
Pt(II) centre and having similar square-planar structure. Therefore, it should be the first 
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compounds to be evaluated for anti-cancer properties. However, gold(III) complexes are 
not very stable under physiological conditions because of their high reduction potential 
and fast hydrolysis rate. Therefore, selection of a suitable ligand to stabilize the complex 
becomes a challenge in the design of gold(III)-based antitumour agents.  This can be 
achieved by chelating the gold(III) center with one or more multidentate ligand to 
enhance the stability of the complex. The synthesis and testing of gold (III) complexes, 
especially with anticancer activity has only begun intensively in the past few years.  
The first organogold(III) complexes that process significant cytotoxic and 
anticancer properties were reported in 1996. 91 Since then, many gold(III) complexes such 
as mono and dinuclear gold(III) were synthesized and tested to be cytotoxic against 
different tumour cells and some of them even showed superior activity against the 
cisplatin-resistant cell lines. 92- 100 The anti-tumour mechanism of gold(III) complexes 
seems substantially different from that of cisplatin. Some suggested that DNA is the 
primary target of gold(III) complexes, but no concrete evidence supported this theory. 101 
In some cases, there is clear evidence of direct DNA damage and apoptosis induced by 
cytotoxic gold(III) complexes, while in other cases, the interactions of gold(III) 
complexes with DNA are significantly different. 102,103 Another report proposed 
mitochondria as a major cellular target for at least some of the gold(III) complexes. 104  
A recent study demonstrated that gold(III) meso-tetraarylporphyrins (Figure 16), 
(28) significantly prolonged the survival of hepatocellular carcinoma HCC-bearing 
rats.105 It was also observed that gold(III) compound induced necrosis and apoptosis in 
the tumour tissues, but not in the normal liver tissues. Various gold(III) compounds with 
zero to three carbon–gold bonds were also evaluated for their ability to inhibit TrxR and 
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the growth of MCF-7 cancer cells in vitro. The two carbon–gold bonds and one 
exchangeable group that could interact with biological ligands were found to be a better 
choice for gold-based inhibitors of TrxR. 105 
While mononuclear gold(I) dithiocarbamate compounds showed comparable 
activity against cisplatin, their gold(III) analogs displayed superior cytotoxicity than 
cisplatin with particular potency against lymphoproliferative-type HL60 and Daudi 
cancer cells. The cytotoxic effect occurred within 24-48 hours and the mechanism of cell 
death was shown to be by apoptosis. 98 A recent study showed that gold complexes target 
proteins but not DNA. Dou et al., have investigated gold(III) dithiocarbamates for their 
anticancer activity and showed that their primary target is the proteasome. Treatment of 
human breast tumour-bearing nude mice with a gold(III) dithiocarbamate complex 
resulted in significant inhibition of tumour growth, associated with proteasome inhibition 













(26) (27)  
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Figure 16 Chemical structures of Dinuclear gold complex (26) and Neutral 
gold(III) compound (27), gold(III) meso-tetraarylporphyrins complexes (28) 
 
1.4 Statement of Purpose 
The interest in phosphinegold(I) thiolates as an anti-cancer agent developed as a 
result of the discovery of cytotoxicity of phosphinegold(I) thiolates. As mentioned 
earlier, phosphinegold(I) thiolates were found to be more cytotoxic than gold thiolates 
and phosphiengold(I) chloride analogues. Moreover, some biological active thiols were 
reported to provide therapeutic effect on cancer patients. The focus of this thesis is 
therefore to couple phosphinegold(I) and biologically active thiols to generate 
biologically active compounds. Together with the available knowledge of the mechanism 
of action of gold complexes as “prodrug”, the derived complexes are believed to possess 
the biological activity against cancer upon administration into the body. The therapeutic 
benefits from both gold and thiol can then be realised. 
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This thesis is divided into two main sections. The first part is to focus on the 
synthesis of thiocarbamate ligands with phosphinegold(I) entities. Series of different 
ligands will be synthesized and then used to couple with different phosphinegold(I). The 
derived compounds will be characterized to confirm the structure. 
The second part of the thesis will involve the biological evaluation of the 
synthesised complexes on a range of 7 human cancer cell lines and normal human 
fibroblast in the hope that the complex would provide therapeutic effect. The selected 
descriptors of each compound will also be evaluated with the aim to understand the 
quantitative structure activity relationship of the compounds synthesized. Computer 
calculator Plugin (Marvin software) will be used to generate the descriptor data. The 
correlation of the derived descriptors and the biogical result can be examined. 
In summary, the objectives of this research are as follows: 
1. Synthesize and characterize the thiocarbamate ligands, phosphinegold(I) 
chloride and derived phosphinegold(I) thiolate. 
2. Evaluate in vitro the biological activity of the thiocarbamate ligands and 
phosphinegold(I) thiolate complexes. 
3. Investigate the pharmacokinetics selected descriptors such as Mass, 
logP, logD, polarisability, hydrogen bond acceptor and molecular 
surface volune of the synthesised compounds. 
4. Investigate the quantitative structure-activity relationship of the 
synthesized complexes and the cancer cell lines. 
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2.1 Introduction 
This chapter describes the chemical used for the synthesis of compounds, experimental 
procedures and the basic properties of the compounds. 
 
2.2 Chemicals 
The chemicals and their sources used in the synthesis of the compounds are shown in the 
table 2 below. 


















2 Triethylphosphine 554-70-1 C6H15P 118.2 
 
Strem 
3 Triphenylphosphine 603-35-0 C18H15P 262.3 
 
Strem 
4 Tricyclohexylphosphine 2622-14-2 C18H33P 280.4 
 
Strem 
5 Thiodiglycol 111-48-8 C4H10O2S 122.2 
Sigma-
Aldrich 
6 Ethyl Isothiocyanate 542-85-8 C3H5NS 87.1 
Sigma-
Aldrich 
7 n-propyl Isothiocyanate 628-30-8 C4H7NS 101.2 
Sigma-
Aldrich 






















isothiocyanate 2131-55-7 ClC6H4NCS 169.6 
sigma 
Aldrich 
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No 
 












isothiocyanate 2740-81-0 ClC6H4NCS 169.6 
sigma 
Aldrich 
15 Potassium hydroxide 1310-58-3 KOH 56.1 
Mallinc
krodt 
16 Sodium hydroxide 1310-73-2 NaOH 40.0 
 
Merck 









 Solvents used were of analytical grade from TEDIA and MERCK. All solvents 
and chemicals are commercially available and were used without further purifications. 
2.3 Synthesis of ligands 
 
2.3.1 Synthesis of O-alkyl, N-aryl thiocarbamate ligands, 
S=C(OR’)N(H)Ar 
 
Eighteen thiocarbamate ligands were synthesised using an adapted method from a 
known literature procedure, 108 as described in Scheme 1. The corresponding 
isothiocyanate component was added dropwise to KOH (1 mol equiv) in R’OH (25 ml). 
Concentrated HCl (37%) was then added dropwise to this solution. The mixture was 
stirred for at least one hour. The product was then extracted from the aqueous solution 
with CHCl3. The product was isolated after removal of water and solvent. The product 
was then recrystallised from CHCl3 and other solvents to obtain the crystals. Ligands 
were then characterised to confirm their identity prior to further usage. 
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Where  Ar =  o-PhCl, m-PhCl, p-PhCl 
    o-PhMe, m-PhMe, p-PhMe 
  R’ = Me,  Et and iPr 
Scheme 1 Preparation of S=C(OR′)N(H)Ar 
 
2.3.2 Synthesis of O-alkyl, N-alkyl thiocarbamate ligands, 
S=C(OR’)N(H)R’’  
 
Nine thiocarbamate ligands were synthesised using the similar procedure as above 




  Where R′ = Me, Et and iPr 
   R″ = Et, nPr and iPr 
Scheme 2 Preparation of S=C(OR’)N(H)R” 
 
 Basic physical data of the Thiocarbonate ligands are shown in Table 3. 












1 L01 2ClPhNHCSOMe C8H8ClNOS 201.67 Solid CHCl3/Hexane 
 
2 L02 2ClPhNHCSOEt C9H10ClNOS 215.70 Solid CHCl3/Hexane 
 
3 L03 2ClPhNHCSOiPr C10H12ClNOS 229.72 Solid CH2Cl2/Hexane 
 
4 L04 3ClPhNHCSOMe C8H8ClNOS 201.67 Solid EtOH/ CH2Cl2 
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5 L05 3ClPhNHCSOEt C9H10ClNOS 215.70 Solid CHCl3/Hexane 
 
6 L06 3ClPhNHCSOiPr C10H12ClNOS 229.72 Solid CHCl3/Hexane 
7  L07 
 
4ClPhNHCSOMe C8H8ClNOS 201.67  Solid  CHCl3/Hexane 
8  L08 
 


























































































iPrNHCSOEt C6H13NOS 147.24 Oil - 
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iPrNHCSOiPr C7H15NOS 161.26 Oil - 
 
2.4 Synthesis of gold chloride precursors 
 
2.4.1 Triorganophosphinegold(I) chlorides, R3PAuCl (R = Ph, Cy and 
Et)  
 
Although some of the triorganophosphinegold(I) chlorides are commercially 
available, for the purpose of this study, all phosphinegold(I) chlorides were synthesised 
in-house by a known literature procedure (as shown in Scheme 3). 109 Sodium 
tetrachloroaurate(III) dihydrate was dissolved in a deoxygenated water:acetone (3:1) 
mixture. The mixture was cooled in an ice-bath under nitrogen. The gold salt was reduced 
by dropwise addition of excess thiodiglycol over 45 minutes. Then one equivalent of the 
dissolved corresponding phosphine in acetone was added to the solution. The precipitated 
product was filtered followed by its recrystalisation using dichloromethane layered with 




R'''3P -AuCl  
Where R’’’ = Ph, Cy and Et 
Scheme 3 Preparation of mononuclear triorganophosphinegold(I) chlorides 
 
 
Three triorganophosphinegold(I) chlorides, namely, triphenylphosphinegold(I) 
chloride, tricyclohexylphosphinegold(I) chloride and triethylphosphinegold(I) chloride 
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have been successfully synthesised and characterized. Table 4 represents the physical 
data  of triorganophosphinegold(I) chlorides. 
 
 





Label Compound Formula 
Molecular 

















Et3PAuCl C6H16AuClP 350.58 Solid  CH2Cl2/ EtOH 
 
2.5 Synthesis of targeted phosphinegold(I) thiolates 
 
The triorganophosphinegold(I) thiolates have been synthesised using established 
procedures as illustrated in Scheme 4. 110 The triorganophosphinegold(I) chloride 
precursor was dissolved in CH2Cl2/EtOH and the corresponding ligand in the presence of 
a base (NaOH) in ethanol was added and stirred for one hour.  The solvent is evaporated 
under reduced pressure and the product recrystallised with various solvents to obtain the 
suitable crystals for X-ray diffraction characterization. The physical data of 




Au ClR'''3P R'''3PAu-S=C(OR')NR"  
Where  Ar =  o-PhCl, m-PhCl, p-PhCl 
    o-PhMe, m-PhMe 
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  R’ = Me,  Et and iPr 
    R″ = Et, nPr and iPr 
R’’’ = Ph, Cy and Et 
Scheme 4 Synthesis of targeted triorganophosphinegold(I) thiolates 
 
Table 5 Physical data for the Phosphinegold(I) thiolates 
 




State Solvent for 
crystalisation 




solid EtOH/ CH2Cl2 




673.95 solid EtOH/ CH2Cl2 




687.97 solid CHCl3/Hexane 




659.92 solid EtOH/ CH2Cl2 




673.95 oil - 




687.97 oil - 




659.92 solid EtOH/ CH2Cl2 









687.97 oil - 




639.50 solid EtOH/ CH2Cl2 




653.53 solid EtOH/ CH2Cl2 




667.56 oil - 




639.50 solid EtOH/ CH2Cl2 




653.53 oil - 




667.56 oil - 




678.06 solid EtOH/ CH2Cl2 




692.09 solid CHCl3/Hexane 
Chapter 2  Experimental Procedures 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities 45




State Solvent for 
crystalisation 




706.12 solid EtOH/Hexane 




678.06 Solid EtOH/ CH2Cl2 




692.09 solid EtOH/Hexane 




706.12 oil - 




678.06 solid EtOH/ CH2Cl2 




692.09 solid ACN/ CH2Cl2 









657.64 solid EtOH/ CH2Cl2 




671.67 solid CHCl3/Hexane 









657.64 oil - 




671.67 solid EtOH/ CH2Cl2 




685.70 solid EtOH/ CH2Cl2 




515.79 oil - 




529.81 oil - 




543.84 oil - 




515.79 oil - 




529.81 oil - 




543.84 oil - 




515.79 Solid EtOH/ CH2Cl2 




529.81 oil - 




543.84 oil - 
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State Solvent for 
crystalisation 




495.37 oil - 




509.40 oil - 




523.42 oil - 




495.37 oil - 




509.40 oil - 




523.42 oil - 




577.43 oil - 




591.46 oil - 




605.50 oil - 




591.46 solid EtOH/ CH2Cl2 




605.48 solid EtOH/ CH2Cl2 




619.51 oil - 




591.46 oil - 




605.48 solid EtOH/ CH2Cl2 




619.51 oil - 




595.57 oil - 




609.60 oil - 




623.63 oil - 




609.60 oil - 




623.63 oil - 




637.65 oil - 




609.60 oil - 
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State Solvent for 
crystalisation 














433.30 oil - 




447.33 oil - 




461.35 oil - 




447.33 oil - 




461.35 oil - 




475.38 oil - 




447.33 oil - 




461.35 oil - 




475.38 oil - 




495.37 oil - 




509.40 oil - 




667.56 oil - 




671.67 oil - 
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3.1 Introduction 
 
This chapter describes the characterization of the synthesized compounds.  
3.2 Instrumentation 
 
3.2.1 Infrared spectroscopy 
 
A Bio-Rad FTS165 FTIR spectrophotometer was used as an instrument for 
recording the infrared spectra for compounds on KBr disc. 
3.2.2 Nuclear Magnetic Resonance (NMR) 
 
A Bruker ACF300 FT NMR spectrometer operating at 300.145 and 75.479 MHz 
was used for recording 1H, and 13 NMR spectra respectively, with chemical shifts relative 
to tetramethylsilane. The same equipment was also used for recording 31P NMR data 
operating at  121.442 MHz with chemical shifts recorded relative to 85 % aqueous 
H3PO4. Chemical shifts are reported in parts per million (ppm). The residual solvent peak 
was used as an internal reference. 
3.2.3 Mass spectrometry 
 
All high resolution ESI mass spectra were obtained on a Finnigan/MAT 95XL-T 
spectrometer. 
3.2.4 Microanalysis 
Perkin Elmer PE 2400 CHN Elemental Analyser was used for microanalysis. 
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3.2.5 Melting point 
 
Melting points were routinely determined on a Buchi Melting Point B-540 
melting point apparatus used for melting point measurement for solid compounds. 
3.2.6 Crystallography 
 
 X-ray data were collected on a Bruker AXS SMART CCD diffractometer using 
Mo-Kα radiation at 183 K and θmax was 30.0 º. Data were reduced (SMART & SAINT) 
and corrected for absorption effects (SADABS). The structure was solved by heavy-atom 
methods (PATTY in DIRDIF) and refined anisotropic displacement parameters, H atoms 
in calculated positions, and a weighting scheme of the form w = 1/[σ2(Fo2) + 0.0051P2 + 
0.4062P] where P = (Fo2 + 2Fc2)/3) on F2 (SHELXL-97). The PublCIF software was used 
to prepare the crystallographic structure and structure data.111 All crystal structures in this 
thesis were solved and refined by A/P Edward Tiekink. 
3.3 Characterisation 
3.3.1 Physical data of triorganophosphinegold(I) chlorides 
Triorganophosphinegold(I) chlorides were synthesized for use as the starting 
material for the phosphinegold(I) thiolate complexes. The procedures were described in 
Chapter 2. The compounds characterized by NMR, IR and Elemental Analysis. Table 6 
shows the physical data off the triorganophosphinegold(I) chlorides. IR and Elemental 
analysis of the compounds are shown in Table 7. Spectroscopic data were compared with 
the available literature and found to be in-line with the publications.108, 112, 113 
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Table 6 Physical data of novel triorganophosphinegold(I) chlorides 
 
No Label Complex Yield (%w/w) Colour M.p (oC) 
1 AU1 (Ph)3PAuCl 75 Colourless 170-171 
2 AU2 (Cy)3PAuCl 78 Colourless 163-165 
3 AU3 (Et)3PAuCl 68 Colourless 121-123 
 
Table 7 IR and Elemental Analysis of the phosphinegold(I) chlorides 
 
Complex IR (cm-1) Microanalysis (%) 
No Label  υ(C-H) C (Calc) H (Calc) 
1 AU1 (Ph)3PAuCl 2962 m 43.56(43.70) 3.52(3.06) 
2 AU2 (Cy)3PAuCl 2923 s 42.31(42.16) 6.25(6.49) 
3 AU3 (Et)3PAuCl 1431 m 20.57(20.56) 4.52(4.31) 
 
3.3.2 Characterisation of Thiocarbamate Ligands 
The ligands were characterised by spectroscopic methods using NMR and IR. 
Elemental analysis, ESI, melting point and X-ray crystallography were also carried out 
for the crystalline ligands. However melting point and X-ray crystallography were not 
performed for alkyl thiocarbamate series because the derived ligands are in oils. Table 10 
and 11 in the Appendix 2, illustrate the physical data, melting points, elemental analysis 
and IR results of the ligands. Characteristic bands of the O-alkyl, N-aryl 
thionocarbamates corresponds to the N-H, C-O and C=S stretches.108 Figure 17 illustrates 
the labelling scheme for the compound. Table 12 and 13 in the Appendix demonstrates 
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the 1H and 13C{1H} NMR assignments, and multiplicities of the ligands. The 1H and 13C 
NMR data for the thiocarbamate ligands were determined in CDCl3. Compounds with 
crystalline form have been characterised by X-ray crystallography by A/P E.R.T. Tiekink 
(currently at the Department of Chemistry, The University of Texas at San Antonio, 


























R= Me, Et, iPr





Figure 17 Labeling scheme for the thiolcarbamate ligands  
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3.3.3 Characterisation of Phosphinegold(I) Thiolates 
 Seventy seven phosphinegold(I) thiolates have been prepared by the 
reaction of the phosphinegold(I) chloride precursor, the respective thiol and NaOH in 
ethanol solution as explained in Chapter 2. The complexes are isolated in reasonable 
yields and characterised NMR, IR, elemental analysis as well as X-ray crystallography to 
confirm the identity of the synthesised compounds. The spectroscopic results were 
compared against literature data available.108 The labeling scheme for both the thiolates 
and phosphines is illustrated in Figure 18. Tables 16 and 17 in the Appendix 2 display the 
1H, 13C{1H} and 31P{1H} NMR assignments and multiplicity of the Phosphinegold(I) 
thiolates. The 1H NMR data for the phosphinegold(I) thiolate  series of complexes were 
determined in CDCl3. The 1H NMR data were consistent with the formulation of the 
product.  13C NMR data shows one resonance for each chemically equivalent C atom. 
The chemical shifts and the 13C-31P coupling constants of the carbon resonance assigned 
are consistent with the complexes. 
The 31P resonances are in the range expected for these phosphinegold(I) O-alkyl, 
N-arylthionocarbamate complexes. The 31P resonances were observed to shift downfield 
in the range of 1 to 5 ppm from that of the observed precursor phosphinegold(I) chloride, 
as expected from the more deshielded P nucleus which would result from its coordination 
to the metal center. Table 14 in the Appendix 2 illustrates the physical and analytical data 
of Phosphinegold(I) Thiolates. 
Characteristic bands of the O-alkyl, N-arylthionocarbamates correspond to the 
C=N and C=S stretches (See Table 15 in the Appendix 2). Also the mass spectra m/z 
value was compared with the calculated value to confirm the structure of the compounds. 
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The molecular structure of some ligands and phosphinegold(I) thiolates obtained 
are shown in Figure 58 to 82 in appendix 3, and geometric parameters related to the 
structures are  reported therein. The gold atom exists in the expected linear geometry 
defined by phosphorus and sulfur atoms. The thiocarbamate ligand coordinates to gold in 
a monodentate fashion.117-119  
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4.1 Introduction 
Biological activity is an expression of the effects (positive or adverse) of a drug or 
substance on living tissue studied. Substance’s toxicity is often used as a representative of 
the biological acitivity. In this study, in vitro cytotoxicity experiments of the synthesised 
Phosphinegold(I) Thiolates and Thiocarbamate ligands with cell lines indicated in Table 
16 were carried out in the laboratory.  
The in vitro assay methods (standard colorimetric - MTT and MTS assays) are 
often used for measuring the activity of enzymes that reduces MTT or MTS + PMS to 
formazan, yielding a purple color.  However, fluorometric microculture cytotoxicity 
assay (FMCA) is used for this study as it is simple, rapid and seems to adequately 
provide relevant cytoxicity data. It is based on the measurement of fluorescence 
generated from the hydrolysis of fluorescein diacetate (FDA) to flurorescein by cells with 
intact plasma membranes.  
The purpose of this chapter is to study the biological activity of the synthesised 
phosphinegold(I) thiolates and Thiocarbamate ligands. Previous studies showed that 
thiolate compounds such as 6-Mercaptopurine (6-MP) is an immunosuppressive drug 
used to treat leukemia.121 However if used as a single agent, it has limited use in therapy. 
Another thiolate compound in focus is thiocarbamate. Thiocarbamate compounds in 
general are known for their use as herbicides, which are poisonous causing clinical signs 
including tremor, dyspnea, salivation, vomiting and bloat. However, some carbamates are 
used in human pharmacotherapy, such as the cholinesterase inhibitors neostigmine and 
rivastigmine, whose chemical structure is based on the natural alkaloid physostigmine.122 
Another study showed anticancer activity correlations of carbamates and thiocarbamates. 
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It was found that aromatic carbamates and thiocarbamates have shown good activity 
against P-388 and poor activity against L-1210. 
Phosphinegold(I) chloride with general structure of R3PAuCl also exhibited a 
certain potency aginst cancer cell lines. For example, tetrakis((trishydroxymethyl) 
phosphine)gold(I) chloride has been investigated for its antitumour properties and found 
to exhibit the growth of the tumour. 123 
The focus of this study will be on the coupling of thiocarbamate ligands with 
phosphine gold(I) chloride which will generate a series of phosphinegold(I) thiolates. It 
has been demonstrated that triorganophosphinegold(I) 2-mercaptobenzoates and 6-
mercaptopurinates are potentially cytotoxic against certain human cancer cell lines, 
particularly the H226 (non-small cell lung cancer) and A498 (renal cancer) cell lines. The 
previous encouraging cytotoxic results of such complexes provide the impetus for further 
cytotoxicity studies of phosphinegold(I) thiolate against several other human cancer cell 
lines.37, 38 
 The in vitro studies of the above synthesized compounds were carried to examine 
the biological activity of these compounds. 
 
4.2 Biological studies of Phosphinegold(I) thiolates in cancer 
cell lines 
Seventy seven phosphinegold(I) thiolates and twenty seven of their corresponding 
ligands synthesised in Chapter 2 were used for the this biological studies against 7 human 
derived cancer cell lines and a normal human fibroblast (HF). Cancer cell lines were from 
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Department of Physiology, and Department of Pharmacy, National University of 
Singapore. 
 
Table 8 Cancer cell lines and human fibroblast 
 
Names Cell lines 
A498 Renal Cancer 
HT-29 Colon carcinoma 
HepG2 Liver cancer 
MCF-7 Breast carcinoma 
NCI - H1299 Non-small cell lung 
OVCAR3 Ovarian cancer 
Hela Cervix cancer 
HF Human Fibroblast 
 
For biological studies, it is extremely important to prevent any contaminants such 
as air-borne bacteria in the experiments to achieve optimal results, otherwise it can lead 
to irregular growth and fungi or bacterial contaminations. Hence all apparatus and 
solutions prepared were sterilized using autoclaved procedures. All procedures were 
carried out in a Class II Biological Safety Cabinet. The UV radiation was switched on 
prior the start of experiment for at least 20 minutes. The Safety Cabinet is wiped with 
ethanol before and after every use. 
All materials used for tissue culture utilized were prepared and sterilized prior 
purchase from the National University Medical Institute (NUMI) Laboratory Supplies. 
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4.3 Procedures and Analysis 
Cell line culture 
Human derived cell lines were routinely cultivated at 37 oC in an atmosphere of 5 
% CO2 in DMEM (A-498 renal cancer, HT29 colon carcinoma, HF normal human 
fibroblast, HepG2 liver cancer, MCF-7 breast carcinoma, NCI lung cancer, OVCAR3 
ovarian cancer and Hela cervix cancer) and RPMI-1640 (NCI-H1299 non-small cell lung 
cancer, OVCAR ovarian cancer and HepG2 liver cancer) medium supplemented with 10 
% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 µg/ml); and 
subcultured twice weekly to maintain continuous logarithmic growth. The cells were 
harvested from confluent monolayers. 
 
Passage 
This is achieved by first removing the medium, followed by washing with 3 ml of 
1× PBS pH 7.4 (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4 and 0.24 g/L KH2PO4). 1 
ml of 1× Trysin-EDTA (5.0 g porcine trypsin and 2.0 g EDTA. 4Na/L in 0.9 % NaCl, 
diluted 10× with autoclaved deionised water) was added for the removal of the cells from 
the sides of the flasks. 2 ml of medium was added to prevent further action of the 
enzyme; cells were removed using glass pipette and split into different flasks depending 
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Fluorometric Microculture Cytotoxicity Assay  
Compounds were prepared in 10 mM stock solutions, dissolved in DMSO, stored 
at 4 oC, for a maximum period of 4 weeks. The drug cytotoxicity and cell proliferation 
were determined using a semiautomated fluorometric microculture cytotoxicity assay. 
The experiment is based on measurements of the fluorescence generated from the 
hydrolysis of fluorescein diacetate (1 g/ml in DMSO, FDA) to fluorescein by cells with 
intact membranes.  
Approximately 10,000 Cancer and Human Fibroblast cells were seeded into each 
of 96-microwell plates. The plates were incubated at 37 ºC overnight to allow the cells to 
adhere to the bottom. The medium of the plates was then changed to 200 µl medium 
containing the test compounds free as control and the test compounds. Each seeded 
column, of the 96-microwell plate was subsequently added with the studied 
thiocarbamate ligands and phosphinegold(I) thiolates.  Each compound was prepared in 2 
different concentrations i.e 5 and 20 micromolar.  
After an incubation period of 72 hours, the plates were washed with PBS. The 
FDA stock solution was diluted to 2 µg/ml with PBS and 200 µl of this solution was then 
added to each of the control, experimental and blank wells. The plates were incubated for 
30 min at 37 ºC and the fluorescence generated from each well was measured at an 
excitation wavelength of 485 nm and an emission wavelength of 535 nm. In a 
preliminary study the fluorescence was found to be proportional to the number of viable 
cells in the well. 
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Cell survival is presented in the form of a survival index (SI), which is defined as 
the fluorescence in experimental wells expressed as a percentage of that in the control 
wells.  
 
4.4 Results and Discussion 
Cytotoxicity experiments of the phosphine gold(I) complexes and its ligands were 
carried out on a range of different human cancer cell lines including renal cancer cell line 
(A-498), colon cancer cell line (HT-29), non-small lung cancer (NCI), breast cancer cell 
line (MCF-7), ovarian cancer cell line (OVCAR3) and cervix cancer cell line (Hela). All 
compounds were also tested for their toxicity against human fibroblast (HF) cell lines. 
DMSO stock solutions were used for all compounds to enable an appropriate comparison 
between the compounds. 
Phosphorus NMR spectroscopy was used for the investigation of in vitro stability 
of phosphorus containing gold complexes. Two examples of the Phosphinegold(I) 
thiolates were tested in DMSO solution using 31P NMR for a period of 30 days. 31P NMR 
spectroscopic analysis showed no observable decomposition over a period of 30 days in 
DMSO solution, suggesting no ligand displacement prior to use in biological study. 
 Cell survival data derived from each column of the 96-microwell plate was tested 
for variance against the control using data analysis tool (F-Test, Two-Sample for 
Variances) in Microsoft Excel. When the P value derived from the test is greater than 
0.05, it indicates significant variability in the control and experimental columns. 
Thiocarbamate ligands at both concentrations (5 and 20 micromolar) showed P value 
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greater than 0.05 for most experiments across all cell lines. This observation suggests 
minimal variability in cell survival between control and individual experimental columns.  
The variance analysis for the Phosphinegold(I) Thiolates also suggests minimal 
variance in cell survival between control and individual experimental columns at low 
concentration, however, it was observed that the variance is significant at the high 
concentration. It can be seen clearly from the data that the variability of the cell survival 
at high concentration is very low as most, if not all cells were killed.  
The mean testing was then conducted using t-Test. The method for testing the 
mean depends on the result from the F test. In the event that the variance in cell survival 
between control and individual experimental columns was insignificant, t-test, Two-
Sample Assuming Equal Variances method was used. If the variance between the control 
and the experiment column was significant, t-test Two-Sample Assuming Unequal 
Variances method is used. The mean testing provided evidence suggesting whether the 
compounds exhibit any biological activity as compared to control. If the P value derived 
from the test is greater than 0.05, it indicates that the mean of the control and 
experimental columns is insignificant. Thiocarbamate ligands at high concentration (20 
micromolar) showed P value greater than 0.05 for most experiments across all cell lines. 
This observation suggests there is no significant difference in cell survival between 
control and individual experimental columns. There are however, some exceptional cases 
that showed P value less than 0.05 which suggested that there are some biological 
acitivity of the particular Thiocarbamate Ligands on the cell lines. On the other hand, the 
analysis suggested that there is significant difference in cell survival between control and 
individual experimental columns at low concentration of Thiocarbamate ligands. The 
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data suggested that the cell survival increased when the cells were exposed to the 
Thiocarbamate ligands at low concentration. 
The mean analysis for the Phosphinegold(I) Thiolates indicates significant 
difference in cell survival between control and individual experimental columns at both 
concentrations. It can be seen clearly that the mean of the cell survival at high 
concentration is very low as most, if not all cells were killed. However, the data also 
suggested that the cell survival increased upon exposed to the Phosphinegold(I) Thiolates 
at low concentration (i.e 5 micromolar). This observation prompted the suggestion that 
the compounds might expedite the cell growth at low concentrations for both 
Thiocarbamate ligands and Phosphinegold(I) Thiolates. However, there is currently no 
literature reporting on the possibility of cell growth with the treatment of and 
thiocarbamate ligands and gold complexes. 
Statistical analysis indicated that most of Phosphinegold(I) thiolates exhibit a 
certain biological activity towards all cancer cell lines at both concentrations. Some 
Thiocarbamate Ligands also showed the biological activity both high concentrations. 
Apart from the above statistical analysis, Survival Index, can also be used as the 
method to determine the biological activity of the compounds. Survival index (SI), which 
is defined as the fluorescence in experimental wells expressed as a percentage of that in 
the control wells for the thiocarbamate ligands and phosphine gold(I) thiolates are given 
in Figure 19-26 and 27-34 respectively.  
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From the survival index, it is obvious that there is a certain biological activity of 
the Phosphinegold(I) thiolates on the cancer cell lines investigated as can be seen from 
very low survival index of the cancer cells at high concentration i.e. 20 micromolar. 
However, the lower Phosphinegold(I) thiolates concentration at 5 micromolar, afforded 
lesser affects towards all cancer cells indicating initial relationship between the dosage 
and the potency. Figure 36, showed that the average survival index of the Human 
Fibroblast was found to be slightly higher than other cancer cell lines at high 
concentration of phosphinegold(I) thiolates indicating further opportunities to carry out 
detailed study of the cytotoxicity of the respective compounds. Most compounds 
efficiently inhibited the growth of all cell lines at 20 micromolar concentration.  
On the other hands, the thiocarbamate ligands showed some biological activities 
against most cell lines but in lesser extent as compared to Phosphinegold(I) thiolates. The 
survival index was higher as compared to the Phosphinegold(I) thiolates even at high 
concentration. There was little difference between the survival index at high and low 
concentration. The survival index of the Human Fibroblast was found to be similar for at 
both concentrations showing that the ligands possess less effect to Human Fibroblast at 
any concentration (Figure 35).   
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Figure 20 Survival index of Hela cell line against thiocarbamate ligands 
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Figure 22 Survival index of NCI cell line against thiocarbamate ligands 
 
Chapter 4  Biological Activity Studies 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities                                        68


























Figure 24 Survival index of MCF7 cell line against thiocarbamate ligands 
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Figure 26 Survival index of HF against thiocarbamate ligands 
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Figure 30 Survival index of NCI cell line against phosphinegold(I) thiolates 
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Figure 31 Survival index of HepG2 cell line against phosphinegold(I) thiolates 
 
 











Figure 32 Survival index of MCF7 cell line against phosphinegold(I) thiolates 
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Figure 33 Survival index of OVCAR3 cell line against phosphinegold(I) thiolates 
 
 










Figure 34 Survival index of HF against phosphinegold(I) thiolates 
 
Chapter 4  Biological Activity Studies 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities                                        74










Figure 35 Average survival index of all cell lines against thiocarbamate ligands 
 










Figure 36 Average survival index of all cell lines against phosphinegold(I) 
thiolates 
Chapter 4  Biological Activity Studies 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities                                        75
 
Cytotoxicity of Thiocarbamate Ligands 


























Figure 37 Cytotoxicity of Thiocarbamate ligands on A-498 cell line 
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Cytotoxicity of Thiocarbamate ligands 
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Figure 42 Cytotoxicity of Thiocarbamate ligands on MCF7 cell line 
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Cytotoxicity of Thiocarbamate Ligands 

































































Figure 44 Cytotoxicity of Phosphinegold(I) Thiolates on A-498 cell line 
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Cytotoxicity of Phosphinegold(I) Thiolates on 





























Figure 46 Cytotoxicity of Phosphinegold(I) Thiolates on HT29 cell line 
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Figure 47 Cytotoxicity of Phosphinegold(I) Thiolates on NCI cell line 
 
 































Figure 48 Cytotoxicity of Phosphinegold(I) Thiolates on HepG2 cell line 
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Cytotoxicity of Phosphinegold(I) Thiolates 




























Figure 49 Cytotoxicity of Phosphinegold(I) Thiolates on MCF7 cell line 
 
 

































Figure 50 Cytotoxicity of Phosphinegold(I) Thiolates on OVCAR3 cell line 
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Previous studies reviewed that phosphine gold(I) chloride exhibited a certain 
potency towards cancer cell lines but not as promising as phosphinegold(I) thiolates.38 
Further analysis on the cytotoxicity of the Phosphinegold(I) Thiolates and Thiocarbamate 
ligands by plotting the ratio of survival index of Human Fibroblast and each individual 
cell lines have also clearly showed cytotoxicity of these compounds. The same study also 
confirmed that Phosphinegold(I) Thiolates are more cytotoxic than their thiocarbamate 
ligands  and perhaps the phosphinegold(I) chloride analogues. Figure 37-43 showed the 
cytotoxicity of Thiocarbamate ligands and Figure 44-50 represented the cytotoxicity of 
Phosphinegold(I) Thiolates. This emphasized the importance of the phosphine gold and 
the thiolate ligands for biological activity. 
 Besides the above mentioned results, the 3 types of triorganophosphine gold used 
in this study, namely, triphenylphosphine gold(I), tricyclophosphine gold(I) and 
triethylphosphine gold(I) did show a certain potency amongst these compounds. The 
work in this field was motivated by the discovery that cytotoxicity of the gold complexes 
R3PAu(6-MP) showed different potency when R = Cy, Ph and Et.124 The same order of 
cytotoxicity was established from the different phosphines synthesized. The cyclohexyl 
derivative had the highest cytotoxicity followed by the phenyl and ethyl species. 
While there was no hard and fast structure-activity relationship established, as for 
the R3PAuSC(OR’)NR” series, it was observed that  for the Phosphinegold(I) Thiolates, 
the potency varies in the order Et > iPr > Me. The results also indicated that non aromatic 
thiocarbamate ligands exhibit higher cytotoxicity as compared to aromatic thiocarbamate 
ligands. R”= Et was the most promising, in particular against HT29 and NCI cell lines. 
This finding is in contrast with the previous studies that reported greater potency of the 
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aromatic complexed ligands versus uncomplexed ones.37 The funcitional group 
substituent on the aromatic rings of the Thiocarbamate ligands have shown the potency 
varies in the order 3Cl > 4Me > 4Cl > 3Me > 2Cl > 2Me.  Garcia-Orad et al., has 
proposed a possible indication to the mode of action of phosphinegold(1) thiolates that 
the compound readily incorporated into the cytoplasm and in the nuclear fraction to 
induce single-stranded breaks in DNA.125- 127. 
Table 9 below listed the top 20 Phosphinegold(I) Thiolates which exibited the 
highest cytotoxicity against all cell lines. 
 





Ratio Survival index of 
HF/Cell line 
P57 EtNCSOiPrCy3PAu 66.58 
P20 3ClPhNCSOEtCy3PAu 49.27 
P05 3ClPhNCSOEtPh3PAu 40.31 
P50 nPrNCSOEtPh3PAu 39.74 
P62 iPrNCSOEtCy3PAu 39.64 
P47 EtNCSOEtPh3PAu 35.85 
P29 3MePhNCSOEtCy3PAu 32.32 
P49 nPrNCSOMePh3PAu 32.14 
P77 4MePhNCSOiPrEt3PAu 30.85 
P60 nPrNCSOiPrCy3PAu 30.68 
P55 EtNCSOMeCy3PAu 25.84 
P24 4ClPhNCSOiPrCy3PAu 25.24 
P22 4ClPhNCSOMeCy3PAu 24.95 
P56 EtNCSOEtCy3PAu 24.06 
P61 iPrNCSOMeCy3PAu 19.93 
P63 iPrNCSOiPrCy3PAu 19.08 
P06 3ClPhNCSOiPrPh3PAu 19.03 
P18 2ClPhNCSOiPrCy3PAu 18.23 
P46 EtNCSOMePh3PAu 18.15 
P76 4MePhNCSOEtCy3PAu 16.15 
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It is also noted that some of the phosphinegold(I) thiolates were relatively 
sensitive towards the non-small lung cancer cell (NCI), ovarian cancer cell line 
(OVCAR3) and colon carcinoma (HT29) at high concentration. However the selectivity 
against the cell lines were not established. In general, the non-systematic variation 
underscores the difficulty in generating a structure/activity relationship in these 
compounds. Still, the above intriguing in vitro results for all cancer cell line clearly 
prompt for further studies into these series of of Phosphinegold(I) thiolates as highlighted 
in Table 9, in terms of IC50 and possibly in vivo study.  
 
4.5 Conclusion 
Phosphinegold(I) thiolates efficiently inhibited the growth of all cell lines and 
human fibroblast at high micromolar concentrations (i.e. 20 micromolar). However, it 
was demonstrated that phosphinegold(I) thiolates at low concentration (i.e. 5 micromolar)  
had limited cytotoxicity towards all cell lines and human fibroblast. Thiocarbamate 
ligands were found to have little activity against the cell lines.  
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5.1 Introduction 
In Lipinski’s Rule of Five, the prediction of partition coefficient is certainly one 
of the important measure used in identifying "druglikeness". Partition and distribution 
coefficients are measures of how hydrophilic or hydrophobic a chemical is. Hence these 
coefficients are a measure of differential solubility of the compound between these two 
solvents. In the study, the choice of solvents used are normally hydrophillic solvents such 
as water and an hydrophobic one such as octanol.128 When a molecule is ionized at the pH 
of a solution, hydrophilic anion or cation will form, as a result the compound will not 
dissolve in its organic phase. In another words, the increase of the hydrophilic form in the 
aqueous phase is generally a result of the ionization of the compound. According to the 
law of conservation of mass, if the hydrophilicity is high in both aqueous and organic 
phase, its hydrophobicity form will decrease. The partition coefficient of a molecule 
observed in a water / octanol system has been adopted as the standard measure of 
lipophilicity. The observed partition coefficient depends on the support electrolyte 
concentration of the bulk phase the compound is dissolved in. Extra ion-pair forming 
chemical agents added to the aqueous/organic phase may have a significant effect on the 
partitioning behaviour of a molecule. 129 
The partition coefficient is therefore a ratio of concentration of the un-ionized 
compounds between the two solutions. LogP is the logarithm of the ratio of the 




Chapter 5  Calculation of Descriptors 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities                                        87
Partition Coefficient, P = [Organic] / [Aqueous], 
LogP = log10 (Partition Coefficient) 
Where [] = concentration 
Scheme 5 Definition of partition coefficient 
 
LogD is the Log Distribution coefficient at a particular pH. The value is pH 
dependent. LogD at pH 7.4 is generally used to give an indication of the lipophilicity of a 
drug at the pH of blood plasma. LogD is the logarithm of the ratio of the sum of 
concentration of the solute's various forms in one solvent. For un-ionizable compounds, 
LogP  = logD at any pH. It can be expressed as follows; 
 
Distribution Coefficient, D = [Unionised] (o) / [Unionised] (aq) + [Ionised] (aq)
 LogD = log10 (Distribution Coefficient ) 
Where [] = concentration 
Scheme 6 Definition of distribution coefficient 
 
Partition coefficients are useful in estimating the distribution of drugs within the 
body. Hydrophobic drugs (with high partition coefficients) will normally be distributed to 
hydrophobic compartments such as the lipid bilayers of cells while hydrophilic drugs 
(with low partition coefficients) are found in hydrophilic compartments such as blood 
serum. Hydrophobicity of a compound, is therefore an important factor for drug design.  
For example, an oral drug needs to be hydrophobic enough to pass through lipid bilayers 
in the intestine. However, it must not have too high lipophilicity as the drug will need to 
to be distributed to other part of the body or the site. Hydrophilicity determines where the 
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drug is penetrated into a biological membrane. The ideal compound as drug should have 
moderate distribution coefficient for the optimal therapeutic effects. The qualifying range 
(covering more than 80% of the compounds) of the Comprehensive Medicinal Chemistry 
(CMC) database indicates calculated log P is between -0.4 and 5.6, with an average value 
of 2.52 as general guideline.130 
The measured distribution coefficient of a compound is dependent on its 
measurement techniques. Popular techniques include the shake flask and pH metric 
methods. The experimental determination of the LogP value of a compound is a not a 
complicated method, although it may be time consuming. In the past, the these data could 
only be obtained by the measurement techniques.131, 132 However, advancement in the 
computer science and statistics arena has introduced new methods for the determination 
of such descriptors.  It was found that there is an increasing need for reliable estimation 
of LogP values for new compounds, particularly for drug design purposes. It is 
meaningful to obtain the partition coefficients of molecules by calculation or prediction. 
Recent methods and design models have incorporated molecular structure and extent of 
ionization as the primary factors in calculating the partition coefficient.133  
As mentioned earlier, some of the Phosphinegold(I) thiolates have shown 
reproducible anti-tumour activity in mouse tumour models in vivo. However, their 
clinical development as anticancer therapeutics was halted by the lack of selectivity 
between tumour and normal cells and resulted in high toxicity of the compounds. Poor 
selectivity is often related to the compounds’ high lipophilicity that caused general 
membrane permeabilization. Recently there has been much research focusing on 
generating the complexes which have intermediate lipophilic and hydrophilic properties 
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critical for improving the toxicity of this class of compounds by finding a balance 
between cell uptake and binding to extracellular proteins.134, 135 
Apart from the distribution coefficients, LogP  and LogD, other physio-chemical 
data or descriptors that potentially describe the druglikeliness of the synthesized 
compound such as mass, polarisability, polar surface area, refractivity, hydrogen bond 
acceptor, hydrogen bond donor and molecular surface volume of the can also be 
calculated. Molecular mass, Hydrogen bond acceptor and hydrogen bond donor are 
descriptors in Lipinski’s Rule of Five and will be included in the calculation. 
Polarizability is the relative tendency of a charged distribution, like the electron cloud of 
an atom or molecule, to be distorted from its normal shape by an external electric field, 
which may be caused by the presence of a nearby ion or dipole. Polarizability is an 
important factor in the determination of pKa because the more stable each ionized site is 
the more its vicinity is polarizable. Atomic polarizability is altered by partial charges of 
atoms. Polarizability is a property of molecules that has received little interests from 
scientists studying chemical-biological interactions. Recently a new method for the 
measurement of compound polarizability has been developed. It was found that the 
parameter correlates with nerve toxicity of a wide variety of chemicals acting on nerves 
of frogs, rabbits, cockroaches, and humans.136 
Refractivity or molar refractivity is a measure of the total polarizability of a 
molecule. In general, molar refractivity of drug molecules are long known to be 
important features strongly influencing receptor binding, cellular uptake, and 
bioavailability. It is strongly related to the volume of the molecules and to London 
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dispersive forces that have important effects in drug-receptor interactions. It can be 
calculated by the Lorenz-Lorentz formula; 
MR = [(n2 -1)/(n2+2)] * M/ρ 
where M is the molecular weight, n is the refraction index and r the density, and 
its value depends only of the wave longitude of the light used to measure the refraction 
index. For molar refractivity, the qualifying range is between 40 and 130, with an average 
value of 97.137 
The Polar Surface Area (PSA) is defined as the surface sum over all polar atoms, 
(usually oxygen and nitrogen), including also attached hydrogens. It is a descriptor that 
shows good correlation with passive molecular transport through membranes, and so 
allows the estimation of transport properties of drugs. PSA is a commonly used medicinal 
chemistry metric for the optimisation of cell permeability. Molecules with a polar surface 
area of greater than 140 angstroms squared are usually believed to be poor at permeating 
cell membranes. For molecules to penetrate the blood-brain barrier and thus acting on 
receptors in the central nervous system, PSA should be less than 60 angstroms squared. 
Average of PSA for Non-CNS Drugs from Mahar Doan is 56.1 with the range of 3.25 to 
151.138, 139 
5.2 Calculation of LogP and LogD using Marvin software 
Marvin software (ChemAxon Ltd., Hungary) was utilised to calculate the 
descriptors such as mass, LogP partition coefficient, LogD, polarizability, polar surface 
area (PSA), refractivity, hydrogen bond acceptor, hydrogen bond donor and molecular 
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surface volume at physiological pH, i.e., pH = 7.4, of the synthesized compounds.140 The 
calculation method in this software was derived from the atomic physicochemical 
parameters of each molecule. The standard partition coefficient of ionized and unionized 
species calculated from the molecular structure is based largely on the atomic LogP 
increments.141 The extent of ionization at a given pH is obtained from the predicted pKa 
of a molecule. The calculation method also takes into account the effect of the counterion 
ion concentration on logD and LogP.142 
Some modifications for improvement from the original method were made in the 
software, such as accommodation of electron delocalization, contribution of ionic form 
and most importantly, incorporating new atom types such as sulfur, carbon, nitrogen and 
metal atoms. This makes Marvin software the preferred choice for the prediction of the 
synthesized compounds studied in this thesis as they are organometallic compounds with 
thiolate ligands.  
The method described by Viswanadhan was reported to be effectively use for 
prediction of the octanol-water coefficient of 129 molecules, which were not included in 
the parametrization procedure. The calculated values showed a low standard deviation of 
0.497 and a good correlation coefficient of 0.876. Statistical results indicated an 
acceptable model on the calculation method for the prediction of synthesized 
compounds.137 
LogP and and LogD of the thiocarbamate ligands and the phosphine gold(I) 
thiolate synthesised compound ranges from 0.92 to 4.01 and 2.58 to 9.75 respectively. 
LogP for most of the ligands are lower than the Phosphinegold(I) thiolates. 
Phosphinegold(I) thiolates exhibited LogP outside the optimal range derived from 
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predictive models for the selective accumulation of delocalized lipophilic cations (DLCs) 
in cancer cells based on lipophilicity.144 Selective accumulation in tumour cells was 
found for LogP between -2 and 2, with the optimum near 0. Based on the initial 
biological evaluation studied in Chapter 3, the synthesized phosphinegold(I) thiolate 
offered a certain biological activity against all 7 human cancer cell lines and normal 
human fibroblast investigated. Further studies on the detailed toxicity of the complexes 
and the selectively induces apoptosis in cancer cell lines should be carried out to confirm 
the cytotoxicity and quantitative structure-activity relationship of the complexes. 
The average molecular polarizability of the compounds calculated in the Marvin 
software was based on an empirical approach of calculating a square of a sum of atomic 
hybrid components highlighted by K.J. Miller and J. A. Savchik.143 Polarizability of 
thiolate ligands was observed in a range of 13.38 to 24.91. On the other hand, 
phosphinegold(I) thiolates posesses higher value of 33.66 to 64.78. The same trends were 
observed for refractivity which showed values of 33.73 to 64.74 for the ligands and 68.79 
to 148.75 for the range of Phosphinegold(I) thiolates. Indeed, most of the molar 
refractivity of the Phosphinegold(I) thiolates are within the CMC qualifying range of 40 
and 130.130  
The descriptor data for the thiocarbamate ligands and phosphinegold(I) thiolates 
are calculated and shown in Table 18 and 19 respectively. Polar surface area and 
hydrogen bond donor were not reported in the table as the compounds synthesized 
possess only one value. These descriptor will not be used in the next Chapter.  
 
 








Chapter 6 Correlation Of Descriptors And Biological 
Activity 
Chapter 6  Correlation of descriptors and biological activity 
Phosphinegold(I) Thiolates: Synthesis and Biological Activities                                        94
6.1 Introduction 
Although the definite mechanism of action of phosphinegold(I) complexes is not 
well-understood, a few studies have suggested a mitochondrial mode of action that the 
cytotoxic effects of gold(I) complexes are the consequence of binding to DNA. The goal 
is to cause specific cancer cell’s DNA damage which can lead to cell death.145, 146 
However the lack of selectivity between tumour and normal cells often resulted in high 
toxicity of the compounds. It is obvious that poor selectivity is usually related to the 
compounds’ lipophilicity. Recently there has been much research on controlling the 
compounds’ lipophilicity to achieve greater selectivity for tumour cells. A study showed 
a significant correlation between the cytotoxic potential of gold(I) complexes and their 
octanol/water partition coefficients suggesting a promising new chemotherapeutic 
drugs.147 
The investigation on the biological activity of the phosphinegold(I) thiolate on 7 
human cancer cell lines and normal human fibroblast in chapter 3 indicated some positive 
outcome as the compounds exhibited a certain cytotoxic potential on the cell lines 
studied. Furthermore, calculation of the descriptors was carried out in Chapter 5. In this 
current chapter the correlation between the biological activity and the descriptors will be 
investigated.  
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6.2 Correlation of Descriptors and biological activity 
The calculated values of descriptors and biological activity were correlated using 
Microsoft Exel scatter plot for univariate analysis.  
Multivariate analysis of the calculated descriptors and the biological activity was 
also attempted to establish the correlation of the descriptors and the biological activity. 
As individual descriptors may not be able to explain the entire activity of a compound, 
several descriptors might be needed to determine drug-likeness, hence the multivariate 
analysis was carried out.   All descriptors were grouped as one variable and the 
cytotoxicity for all cell lines were grouped as a response. The SIMCA-P+ software was 
utilised to examine the correlation. 
 
6.3 Discussion 
In order to simplify the analysis and also to evaluate the trends of the above 
effects, the ratio survival index of HF over individual cancer cell line was used for the 
studies. The ratio represented the cytotoxicity of the compounds against the cell line with 
respect to the Human Fibroblast. High ratio indicates that the compound has high 
cytotoxic against the cancer cell lines but less toxic to the normal cell. 
 Cytotoxicity is subsequently correlated to all the descriptors. The result did not 
show any correlation between the cytotoxicity and descriptors namely, mass, LogP, 
LogD, polarizability, molecular surface volume, hydrogen bond acceptor and refractivity 
for all cell lines. The correlation was described by correlation coefficient, R2, linear 
dependence between the two variables. The summary of the correlation coefficient, R2 
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were given in Tables 20-29 in the Appendix 5. The correlation coefficient indicated the 
biological activity and the descriptors are independent.  
The multivariate analysis using SIMCA-P+ software afforded similar outcome for 
this study. Figure 83 to 96 in the Appendix 6 showed the correlation between the 
descriptors and the cytotoxicity for the Thiocarbamate ligands. A low predictive power 
for the PLS model was reported at only 2%, indicating there is little correlation between 
the descriptors and the biological activity of these compounds.  
 Figure 97 to 110 in the Appendix 6 illustrated the correlation between the 
descriptors and the cytotoxicity of the Phosphinegold(I) Thiolate. The descriptors can not 
be used to predict the biological activity based on the current model. A low predictive 
power for the PLS model was reported at only 7%, indicating there is little correlation 
between the descriptors and the biological activity of these compounds.  
The multivariate analysis was also carried out using the survival index as 
biological activity for both Thiocarbamate Ligands and Phosphonegold(I) Thiolates. 
There was little correlation of survival index and descriptors predicted. 
The lack of a clear correlation between the biological activity and the descriptors 
could be due to the the non-systematic variation in the experiments which resulted in a 
certain variability in biological activity data used in the analysis. 
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7.1 Final Conclusions 
The preparation of a series of thiocarbamate ligands, gold(I) cholorides and its 
new corresponding phosphinegold(I) thiolate was effectively carried out using the 
reported methodology. The compounds were successfully characterized by the 
spectroscopy methods such as IR, mass spectroscopy and NMR. Some other techniques 
of analysis were also employed to confirm the structure of the compounds such as 
elemental analysis and x-ray crystallography. Some crystallographical structures were 
obtained on the solid compounds confirming the robustness of the synthesis methods.  
The biological activity of the phosphinegold(I) thiolate and their corresponding 
ligands were also carried out on the seven human cancer cell lines and the normal human 
fibroblast. At high concentration of 20 micromolar of the gold(I) complexes, most of the 
cancer cells were killed as can be seen from the low percentage of cancer cells that 
survived. Phosphinegold(I) thiolates were found to be more cytotoxic as compared to the 
thiocarbamate ligands at the same concentration, indicating the importance of the 
phosphine gold(I) function of the molecule.  
 
Descriptors such as molecular mass, logP, logD, polariability, refractivity 
hydrogen bond acceptor and molecular surface volume, of the phosphinegold(I) thiolates 
and its ligands were predicted using a computer software, Marvin. The descriptors were 
used to attempt the study of the quantitative structure-activity relationship. Although the 
compounds’ cytotoxicity were observed on the range of cancer cell lines but the 
quantitative structure activity relationship of the complexes was not established.  There 
was little correlation between the activity and the descriptors’ value observed.  
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In general, such a non-systematic variation underscores the difficulty in 
generating a quantitative structure-activity relationship in these compounds. However, a 
few promising Phosphinegold(I) Thiolates from the above intriguing in vitro results such 
as those listed in Table 9, from tests on the cancer cell lines clearly prompt for further 
studies into these series of Phosphinegold(I) Thiolates. 
 
7.2 Proposed Future Studies 
The present study has shown that the Phosphinegold(I) Thiolates studied are 
cytotoxic against most of human cancer cell lines. However further detailed study on 
cytotoxicity such as the half maximal inhibitory concentration (IC50) and the mechanism 
of anti-tumour action of the Phosphinegold(I) thiolates on the cancer cells can be carried 
out. Cell apoptosis study and ability of the Phosphinegold(I) thiolates to induce apoptosis 
and necrosis of tumour cells will provide greater confidence and insight of the 
mechanism of action of Phosphinegold(I) thiolates. Detailed toxicity studies may give 
better correlation of the biological activity and the descriptors studied and hence the 
structure activity relationship of the gold(I) complexes. A possible in vivo study of the 
compounds could also be pursued. 
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Table 10 Physical and analytical data for thiocarbamate ligands 
 
Yield M.p Microanalysis (%) 
No Label 
Thiocarbamate 
Ligands Colour (%w/w) (oC) C (Calc) H (Calc) N (Calc) S (Calc) 
1 L01 
2ClPhNH 
CSOMe Pale yellow 62 72-74 47.5 (47.7) 4.3 (4.0) 6.9 (7.0) 15.7 (15.9) 
2 L02 
2ClPhNH 
CSOEt Light brown 72 30-32 50.1 (50.1) 4.7 (4.7) 6.5 (7.4) 14.7 (14.8) 
3 L03 
2ClPhNH 
CSOiPr Light brown 68 29-31 51.9 (52.2) 4.9 (5.3) 7.1 (6.1) 12.8 (14.0) 
4 L04 
3ClPhNH 
CSOMe Colourless 75 84-85 47.7 (47.7) 4.2 (4.0) 6.7 (6.4) 15.9 (15.9) 
5 L05 
3ClPhNH 
CSOEt Pale yellow 70 79-81 50.2 (50.1) 4.6 (4.7) 6.7 (7.4) 14.9 (14.9) 
6 L06 
3ClPhNH 
CSOiPr Colourless 65 68-70 52.4 (52.3) 5.2 (5.3) 6.1 (6.1) 13.3 (14.0) 
7 L07 
4ClPhNH 
CSOMe Off white 83 93-94 47.7 (47.7) 4.2 (4.0) 6.7 (6.4) 15.9 (15.9) 
8 L08 
4ClPhNH 
CSOEt Off white 85 101-103 50.2 (50.1) 4.4 (4.7) 6.7 (7.4) 14.5 (14.9) 
9 L09 
4ClPhNH 
CSOiPr Off white 79 96-98 52.2 (52.3) 4.9 (5.3) 6.5 (6.1) 13.5 (14.0) 
10 L10 
2MePhNH 
CSOMe Light brown 83 72-73 59.4 (59.6) 7.8 (7.7) 8.5 (8.4) 17.7 (17.7) 
11 L11 
2MePhNH 
CSOEt Light brown 75 29-31 61.4 (61.5) 6.8 (6.7) 7.7 (7.2) 17.2 (16.4) 
12 L12 
2MePhNH 
CSOiPr Light brown 80 29-31 63.0 (63.1) 6.5 (7.2) 6.8 (6.7) 15.6 (15.3) 
13 L13 
3MePhNH 
CSOMe Pale yellow 76 72-74 59.7 (59.6) 6.2 (7.7) 7.9 (8.4) 17.8 (17.7) 
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Yield M.p Microanalysis (%) 
No Label 
Thiocarbamate 
Ligands Colour (%w/w) (oC) C (Calc) H (Calc) N (Calc) S (Calc) 
14 L14 
3MePhNH 
CSOEt Light brown 70 64-66 61.5 (61.5) 6.5 (6.7) 7.5 (7.2) 16.5 (16.4) 
15 L15 
3MePhNH 
CSOiPr Pale Yellow 25 <25 63.1 (63.1) 7.3 (7.2) 6.8 (6.7) 15.8 (15.3) 
16 L16 EtNHCSOMe Pale yellow 30 <25 - (40.3) - (7.6) - (11.8) - (26.9) 
17 L17 EtNHCSOEt Pale yellow 18 <25 - (45.1) - (8.3) - (10.5) - (24.1) 
18 L18 EtNHCSOiPr Pale yellow 40 <25 - (49.0) - (8.9) - (9.5) - (21.8) 
19 L19 nPrNHCSOMe Pale yellow 28 <25 - (45.1) - (8.3) - (10.5) - (24.1) 
20 L20 nPrNHCSOEt Pale yellow 29 <25 - (49.0) - (8.9) - (9.5) - (21.8) 
21 L21 nPrNHCSOiPr Pale yellow 45 <25 - (52.1) - (9.4) - (8.7) - (19.9) 
22 L22 iPrNHCSOMe Pale yellow 38 <25 - (45.1) - (8.3) - (10.5) - (24.1) 
23 L23 iPrNHCSOEt Pale yellow 52 <25 - (49.0) - (8.9) - (9.5) - (21.8) 
24 L24 iPrNHCSOiPr Pale yellow 47 <25 - (52.1) - (9.4) - (8.7) - (19.9) 
25 L25 
4MePhNH 
CSOMe Light yellow 78 105-107 59.3 (59.6) 7.2 (7.7) 7.9 (8.4) 17.7 (17.7) 
26 L26 
4MePHNH 
CSOEt Light brown 83 97-99 60.5 (61.5) 6.6 (6.7) 7.4 (7.2) 16.3 (16.4) 
27 L27 
4MePhNH 
CSOiPr Light yellow 46 <25 - (63.1) - (7.2) - (6.7) - (15.3) 
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Table 11 IR data of the thiocarbamate Ligands 
 
IR (cm-1) 
No Label Thiocarbamate Ligands υ(N-H) υ(C=S) υ(C-O) 
1 L01 2ClPhNHCSOMe 3325 br 1213 s 1053 m 
2 L02 2ClPhNHCSOEt 3365 br 1194 s 1035 m 
3 L03 2ClPhNHCSOiPr 3395 br 1206 s 1097 m 
4 L04 3ClPhNHCSOMe 3214 br 1210 s 1051 m 
5 L05 3ClPhNHCSOEt 3244 br 1198 m 1037 s 
6 L06 3ClPhNHCSOiPr 3219 br 1202 m 1090 m 
7 L07 4ClPhNHCSOMe 3235 br 1209 m 1053 m 
8 L08 4ClPhNHCSOEt 3239 br 1204 m 1096 m 
9 L09 4ClPhNHCSOiPr 3198 br 1207 s 1091 s 
10 L10 2MePhNHCSOMe 3234 br 1209 m 1061 m 
11 L11 2MePhNHCSOEt 3219 br 1202 m 1049 s 
12 L12 2MePhNHCSOiPr 3212 br 1205 s 1095 s 
13 L13 3MePhNHCSOMe 3390 br 1210 m 1061 s 
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IR (cm-1) 
No Label Thiocarbamate Ligands υ(N-H) υ(C=S) υ(C-O) 
14 L14 3MePhNHCSOEt 3238 br 1206 m 1044 m 
15 L15 3MePhNHCSOiPr 3408 br 1206 m 1095 m 
16 L16 EtNHCSOMe 3270 br 1212 m 1057 m 
17 L17 EtNHCSOEt 3262 br 1205 s 1056 m 
18 L18 EtNHCSOiPr 3287 br 1214 m 1052 m 
19 L19 nPrNHCSOMe 3280 br 1206 s 1079 m 
20 L20 nPrNHCSOEt 3260 br 1215 s 1101 s 
21 L21 nPrNHCSOiPr 3260 br 1204 m 1098 s 
22 L22 iPrNHCSOMe 3411 br 1215 m 1037 m 
23 L23 iPrNHCSOEt 3254 br 1206 m 1040 m 
24 L24 iPrNHCSOiPr 3266 br 1216 s 1100 s 
25 L25 4MePhNHCSOMe 3415 br 1216 s 1047 m 
26 L26 4MePHNHCSOEt 3225 br 1204 s 1040 s 
27 L27 4MePhNHCSOiPr 3414 br 1209 s 1044 m 
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No Label 
Thiocarbamate 
Ligands δ (ppm)  
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w/w) M.p (oC) C (Calc) H (Calc) N (Calc) S (Calc) 
1 P01 
2ClPhNCSOMe 
Ph3PAu Colourless 75 183-184 47.3 (47.3) 3.3 (3.4) 2.1 (2.1) 5.2 (4.9) 
2 P02 
2ClPhNCSOEt 
Ph3PAu Colourless 68 165-167 47.8 (48.1) 3.4 (3.6) 1.9 (2.1) 4.6 (4.8) 
3 P03 
2ClPhNCSOiPr 
Ph3PAu Colourless 72 143-144 48.9 (48.9) 3.8 (3.8) 2.0 (2.0) 4.8 (4.7) 
4 P04 
3ClPhNCSOMe 










Yellow 52 <25 - (48.9) - (3.8) - (2.0) - (4.7) 
7 P07 
4ClPhNCSOMe 
Ph3PAu Colourless 78 195-196 47.2 (47.3) 3.2 (3.3) 2.4 (2.1) 5.0 (4.9) 
8 P08 
4ClPhNCSOEt 





Yellow 61 <25 - (48.9) - (3.8) - (2.0) - (4.7) 
10 P10 
2MePhNCSOMe
Ph3PAu Colourless 80 125-127 49.3 (50.7) 3.6 (3.9) 2.1 (2.2) 6.9 (5.0) 
11 P11 
2MePhNCSOEt 





Yellow 45 <25 - (52.2) - (4.4) - (2.1) - (4.8) 
13 P13 3MePhNCSOMe Colourless 83 135-137 50.6 (50.7) 4.0 (3.9) 2.1 (2.2) 4.9 (5.0) 
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Yellow 62 <25 - (52.2) - (4.4) - (2.1) - (4.8) 
16 P16 
2ClPhNCSOMe 
Cy3PAu Colourless 85 160-162 46.1 (46.1) 5.8 (6.0) 2.1 (2.1) 6.2 (4.7) 
17 P17 
2ClPhNCSOEt 
Cy3PAu Colourless 76 181-182 46.9 (46.9) 6.2 (6.1) 2.1 (2.0) 4.8 (4.6) 
18 P18 
2ClPhNCSOiPr 
Cy3PAu Colourless 83 175-177 47.2 (47.6) 6.0 (6.3) 2.1 (2.0) 4.6 (4.5) 
19 P19 
3ClPhNCSOMe 
Cy3PAu Colourless 72 141-143 46.2 (46.1) 6.0 (6.0) 1.9 (2.1) 4.9 (4.7) 
20 P20 
3ClPhNCSOEt 





Yellow 55 <25 - (47.6) - (6.3) - (2.0) - (4.5) 
22 P22 
4ClPhNCSOMe 
Cy3PAu Colourless 78 130-133 46.1 (46.1) 6.2 (6.0) 2.2 (2.1) 6.4 (4.7) 
23 P23 
4ClPhNCSOEt 
Cy3PAu Colourless 75 133-135 47.1 (46.9) 6.2 (6.1) 1.8 (2.0) 5.8 (4.6) 
24 P24 
4ClPhNCSOiPr 
Cy3PAu Colourless 79 124-126 47.3 (47.6) 6.2 (6.3) 1.9 (2.0) 4.6 (4.5) 
25 P25 
2MePhNCSOMe
Cy3PAu Colourless 82 131-132 49.0 (49.3) 6.7 (6.6) 2.1 (2.1) 4.8 (4.9) 
26 P26 
2MePhNCSOEt 
Cy3PAu Colourless 75 144-146 50.0 (50.1) 6.8 (6.8) 1.9 (2.1) 5.1 (4.8) 
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w/w) M.p (oC) C (Calc) H (Calc) N (Calc) S (Calc) 
27 P27 
2MePhNCSOiPr





Yellow 45 <25 - (49.3) - (6.6) - (2.1) - (4.9) 
29 P29 
3MePhNCSOEt 
Cy3PAu Colourless 80 142-144 50.0 (50.1) 6.6 (6.8) 2.0 (2.1) 4.6 (4.8) 
30 P30 
3MePhNCSOiPr






























Yellow 55 <25 (35.3) - (4.8) - (2.6) - (5.9) 
37 P37 
4ClPhNCSOMe 










Yellow 65 86-87 34.6 (35.3) 4.5 (4.8) 2.3 (2.6) 6.7 (5.9) 
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Yellow 54 <25 - (47.6) - (4.5) - (2.3) - (5.3) 
49 P49 
nPrNCSOMe 
Ph3PAu Colourless 85 156-158 43.6 (46.7) 5.1  (4.3) 2.9  (2.4) 8.6 (5.4) 
50 P50 
nPrNCSOEt 










Yellow 45 <25 - (46.7) - (4.3) - (2.4) - (5.4) 
      Appendix 2 







w/w) M.p (oC) C (Calc) H (Calc) N (Calc) S (Calc) 
53 P53 
iPrNCSOEt 








































Yellow 53 <25 - (45.3) - (7.1) - (2.3) - (5.3) 
62 P62 
iPrNCSOEt 
Cy3PAu Colourless 68 148-150 46.2 (46.2) 7.0 (7.3) 2.3 (2.3) 5.2 (5.1) 
63 P63 
iPrNCSOiPr 










Yellow 35 <25 - (29.5) - (5.6) - (3.1) - (7.2) 
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Yellow 61 <25 (50.8) - (6.9) - (2.0) - (4.7) 
77 P77 
4MePhNCSOiPr 
Et3PAu Yellow 52 <25 (39.0) - (5.6) - (2.7) - (56.1) 
 
 
- data not available
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Table 15 IR data for phosphinegold(I) thiolates 
 
IR (cm-1) 
No  Label 
Phosphinegold(I) 
Thiolates υ(C-S) υ(C-N) 
1 P01 2ClPhNCSOMePh3PAu 1148 m,  885 m 1429 m 
2 P02 2ClPhNCSOEtPh3PAu 1142 s, 903 m 1433 m 
3 P03 2ClPhNCSOiPrPh3PAu 1216 s, 909 m 1437 m 
4 P04 3ClPhNCSOMePh3PAu 1146 s, 868 m 1429 m 
5 P05 3ClPhNCSOEtPh3PAu 1216 s, 932 m 1437 m 
6 P06 3ClPhNCSOiPrPh3PAu 1216 s, 931 m 1437 s 
7 P07 4ClPhNCSOMePh3PAu 1148 s, 881 m 1429 m 
8 P08 4ClPhNCSOEtPh3PAu 1151 s, 910 m 1431 m 
9 P09 4ClPhNCSOiPrPh3PAu 1144 m, 895 m 1437 m 
10 P10 2MePhNCSOMePh3PAu 1138 m, 881 m 1431 m 
11 P11 2MePhNCSOEtPh3PAu 1130 s, 893 m 1433 m 
12 P12 2MePhNCSOiPrPh3PAu 1216 s, 898 m 1438 m 
13 P13 3MePhNCSOMePh3PAu 1132 s, 819 m 1437 s 
14 P14 3MePhNCSOEtPh3PAu 1176 m, 818 m 1438 m 
15 P15 3MePhNCSOiPrPh3PAu 1216 s, 912 m 1437 s 
16 P16 2ClPhNCSOMeCy3PAu 1155 m, 890 m 1446 s 
17 P17 2ClPhNCSOEtCy3PAu 1165 s, 851 m, 1445 m 
18 P18 2ClPhNCSOiPrCy3PAu 1216 s, 928 m 1447 m 
19 P19 3ClPhNCSOMeCy3PAu 1155 s, 853 m 1443 m 
20 P20 3ClPhNCSOEtCy3PAu 1147 m, 888 m 1447 m 
21 P21 3ClPhNCSOiPrCy3PAu 1152 m, 853 m 1448 m 
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IR (cm-1) 
No  Label 
Phosphinegold(I) 
Thiolates υ(C-S) υ(C-N) 
22 P22 4ClPhNCSOMeCy3PAu 1150 s, 854 m 1485 m 
23 P23 4ClPhNCSOEtCy3PAu 1134 s, 825.5 m 1445 m 
24 P24 4ClPhNCSOiPrCy3PAu 1148 s, 894 m 1447 m 
25 P25 2MePhNCSOMeCy3PAu 1141 m, 888 m 1448 m 
26 P26 2MePhNCSOEtCy3PAu 1157 s, 851 m 1445 m 
27 P27 2MePhNCSOiPrCy3PAu 1136 s, 854 m 1445 m 
28 P28 3MePhNCSOMeCy3PAu 1139 m, 891 m 1448 m 
29 P29 3MePhNCSOEtCy3PAu 1133 m, 891 m 1447 m 
30 P30 3MePhNCSOiPrCy3PAu 1140 m, 889 m 1448 m 
31 P31 2ClPhNCSOMeEt3PAu 1152 m, 852 m 1448 m 
32 P32 2ClPhNCSOEtEt3PAu 1150 s, 892 m 1458 m 
33 P33 2ClPhNCSOiPrEt3PAu 1146 s, 907 1466 s 
34 P34 3ClPhNCSOMeEt3PAu 1171 s, 865 m 1459 s 
35 P35 3ClPhNCSOEtEt3PAu 1148 m, 864 m 1467 m 
36 P36 3ClPhNCSOiPrEt3PAu 1151 m, 870 m 1476 m 
37 P37 4ClPhNCSOMeEt3PAu 1144 s, 833 m 1454 m 
38 P38 4ClPhNCSOEtEt3PAu 1140 m, 832 m 1455 m 
39 P39 4ClPhNCSOiPrEt3PAu 1149 s, 837 m 1455 m 
40 P40 2MePhNCSOMeEt3PAu 1137 s, 889 s 1457 m 
41 P41 2MePhNCSOEtEt3PAu 1136 s, 903 m 1458 m 
42 P42 2MePhNCSOiPrEt3PAu 1142 s, 897 s 1459 m 
43 P43 3MePhNCSOMeEt3PAu 1135 s, 842 m 1456 m 
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IR (cm-1) 
No  Label 
Phosphinegold(I) 
Thiolates υ(C-S) υ(C-N) 
44 P44 3MePhNCSOEtEt3PAu 1128 s, 820 m 1453 m 
45 P45 3MePhNCSOiPrEt3PAu 1138 s, 818 m 1458 m 
46 P46 EtNCSOMePh3PAu 1100 s 1437 s 
47 P47 EtNCSOEtPh3PAu 1101 s 1436 s 
48 P48 EtNCSOiPrPh3PAu 1102 s 1437 s 
49 P49 nPrNCSOMePh3PAu 1101 s 1437 s 
50 P50 nPrNCSOEtPh3PAu 1102 s 1431 s 
51 P51 nPrNCSOiPrPh3PAu 1102 s 1437 s 
52 P52 iPrNCSOMePh3PAu 1101 s 1438 s 
53 P53 iPrNCSOEtPh3PAu 1102 s 1437 s 
54 P54 iPrNCSOiPrPh3PAu 1102 s 1437 s 
55 P55 EtNCSOMeCy3PAu 1112 m 1448 s 
56 P56 EtNCSOEtCy3PAu 1114 m 1148 s 
57 P57 EtNCSOiPrCy3PAu 1214 s 1447 m 
58 P58 nPrNCSOMeCy3PAu 1129 s 1447 m 
59 P59 nPrNCSOEtCy3PAu 1134 m 1448 m 
60 P60 nPrNCSOiPrCy3PAu 1102 m 1448 s 
61 P61 iPrNCSOMeCy3PAu 1114 m 1448 s 
62 P62 iPrNCSOEtCy3PAu 1126 s 1446 s 
63 P63 iPrNCSOiPrCy3PAu 1177 m 1448 m 
64 P64 EtNCSOMeEt3PAu 1040 s 1456 s 
65 P65 EtNCSOEtEt3PAu 1113 m, 870 m 1453 m 
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IR (cm-1) 
No  Label 
Phosphinegold(I) 
Thiolates υ(C-S) υ(C-N) 
66 P66 EtNCSOiPrEt3PAu 1039 s 1456 m 
67 P67 nPrNCSOMeEt3PAu 1154 m, 891 m 1456 m 
68 P68 nPrNCSOEtEt3PAu 1116 m, 888 m 1455 m 
69 P69 nPrNCSOiPrEt3PAu 1103 m, 847 m 1461 m 
70 P70 iPrNCSOMeEt3PAu 1040 s 1455 s 
71 P71 iPrNCSOEtEt3PAu 1040 s 1454 s 
72 P72 iPrNCSOiPrEt3PAu 1151 m, 868 m 1458 s 
73 P73 4MePhNCSOMeEt3PAu 1138 s, 887 s 1456 s 
74 P74 4MePhNCSOEtEt3PAu 1136 s, 824 s 1457 m 
75 P75 4MePhNCSOiPrPh3PAu 1142 m, 909 m 1437 s 
76 P76 4MePhNCSOEtCy3PAu 1143 m, 893 m 1449 m 
77 P77 4MePhNCSOiPrEt3PAu 1150 m, 896 s 1456 m 
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)
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No Label 
Phosphinegold(I)

















All spectra recorded in CDCl3. Abbreviations: s = singlet, d = doublet, q = quartet, m = multiplet, sept= septet 
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Figure 51 Crystallographic structure of 4ClPhNHCSOMe 
 
Crystallographic data:   Monoclinic; P21/n; a = 14.5243 (10) Å, b = 7.7142 (6) Å, c = 
17.2760 (12) Å; β = 110.560 (2)°; V = 1812.4 (2) Å3; Z = 8; Dx = 1.478 g/cm3; R = 
0.043, wR(F2) = 0.121 
Selected geometric parameters:   S—C1= 1.6560(16) Å; O—C1 = 1.3184(18) Å; N—C1 
= 1.3350(19) Å; N—C2 = 1.4138 (19) Å; Cl—C5 = 1.7374(16)Å 
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Figure 52 Crystallographic structure of 4ClPhNHCSOEt 
 
Crystallographic data:   Monoclinic; P21/n; a = 8.7544 (12) Å, b = 4.5159 (6) Å, c 
= 25.794 (4) Å; β = 96.402 (3)°; V = 1013.4 (2) Å3; Z = 4; Dx = 1.414 g/cm3; R = 0.061, 
wR(F2) = 0.153 
Selected geometric parameters:   S—C1= 1.667(2) Å; O—C1 = 1.326(2) Å; N—
C1 = 1.337(3)Å; N—C2 = 1.417(3) Å. Cl—C5 = 1.740(2) Å.114 
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Figure 53 Crystallographic structure of 4ClPhNHCSOiPr 
 
Crystallographic data:   Monoclinic; P21/c; a = 7.1307 (6) Å, b = 19.8847 (17) Å, c = 
8.2842 (6) Å; β = 99.8270 (10)°; V = 1157.40 (16) Å3; Z = 4; Dx = 1.318 g/cm3; R = 
0.044, wR(F2) = 0.121 
Selected geometric parameters:   S—C1= 1.6708(15)Å; O—C1 = 1.3231(17) Å; N—C1 
= 1.3388(18) Å; N—C2 = 1.4197(18)Å; Cl—C5 = 1.7361(15) Å 
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Figure 54 Crystallographic structure of 2MePhNHCSOMe 
 
Crystallographic data:   Triclinic, P1; a = 6.887(2) Å, b = 8.251(2) Å, c = 9.419(2) Å; β = 
101.572(5)°; V = 461.4 Å3; Z = 2; R = 0.045, wR(F2) = 0.140 
Selected geometric parameters:   S—C1=1.670(1) Å ; N—C1 = 1.335(2) Å; N—C2 = 
1.434(2) Å.115 
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Figure 55 Crystallographic structure of 3MePhNHCSOEt 
 
Crystallographic data:   Monoclinic; C2/c; a = 17.975 (2) Å, b = 7.2265 (9) Å, c = 
17.343 (2) Å; β = 110.687 (3)°; V = 2107.6 (4) Å3; Z = 8; Dx = 1.231 g/cm3; R = 0.054, 
wR(F2) = 0.151 
Selected geometric parameters:   S—C1=1.6718(17); O—C1 = 1.325(2) Å; N—
C1 = 1.337(2) Å; N—C2 = 1.4259(19) Å.116 
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Figure 56 Crystallographic structure of 4MePhNHCSOEt 
 
Crystallographic data:   Monoclinic; P21/c; a = 5.9054 (8) Å, b = 7.4497 (10) Å, c = 
11.9638 (16) Å; β = 82.207 (3)°; V = 520.15 (12) Å3; Z = 4; Dx = 1.247 g/cm3; R = 
0.110, wR(F2) = 0.267 
Selected geometric parameters:   S—C1= 1.668(4) Å; O—C1 = 1.321 (4) Å; N—C1 = 
1.338(5) Å; N—C2 = 1.418 (4)Å 
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Figure 57 Crystallographic structure of 2ClPhNCSOMePh3PAu 
 
Crystallographic data:   Monoclinic; P21/n; a = 8.9388 (5) Å, b = 26.2804 (15) Å, c = = 
10.3233 (6) Å; β = 96.5990 (10)°; V = 2409.0 (2)  Å3; Z = 4; Dx = 1.819 g/cm3; R = 
0.036, wR(F2) = 0.090. 
Selected geometric parameters:   Au-P = 2.2510 (11) Å;  Au – S = 2.3087(11) Å; 
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Figure 58 Crystallographic structure of 2ClPhNCSOEtPh3PAu 
 
Crystallographic data:   Monoclinic; P21/n; a = 8.8401 (5) Å, b = 26.0187 (14) Å, c = 
10.8595 (6) Å; β = 94.8500 (10)°; V = 2488.8 (2) Å3; Z = 4; Dx = 1.799 g/cm3; R = 
0.039, wR(F2) = 0.109 
Selected geometric parameters:   Au-P = 2.2576 (11) Å;  Au – S = 2.3131 (11) Å; 
 S—C1= 1.759 (4) Å; O—C1 = 1.359 (5)Å; N—C1 = 1.266 (6) Å; P1—Au—S1 = 
177.44 (4) Å. 
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Figure 59 Crystallographic structure of 3ClPhNCSOMePh3PAu 
 
Crystallographic data:   Monoclinic; P21/c; a = 19.1964 (8) Å, b = 11.7855 (5) Å, c = 
26.0594 (11) Å; β = 107.3280 (10)°; V = 5628.1 (4) Å3; Z = 8; Dx = 1.600 g/cm3; R = 
0.041, wR(F2) = 0.110 
Selected geometric parameters:   Au-P = 2.2421 (10) Å;  Au – S = 2.2905 (12) Å; 
 S—C1= 1.758 (4) Å; O—C1 = 1.354 (5)Å; N—C1 = 1.245 (5) Å; P1—Au—S1 = 
174.62 (4) Å. 
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Figure 60 Crystallographic structure of 4ClPhNCSOMePh3PAu 
 
Crystallographic data:   Monoclinic; P21/n; a = 9.1781 (6) Å, b = 17.5679 (12) Å, c = 
15.5384 (11) Å; β = 104.156 (2)°; V = 2429.3 (3) Å3; Z = 4; Dx = 1.804 g/cm3; R = 
0.033, wR(F2) = 0.095 
Selected geometric parameters:   Au-P = 2.2469 (11) Å;  Au – S = 2.3017 (11) Å; 
 S—C1= 1.755 (4); O—C1 = 1.353 (5) Å; N—C1 = 1.271 (6) Å; P1—Au—S1 = 175.14 
(4) Å. 
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Figure 61 Crystallographic structure of 4ClPhNCSOEtPh3PAu 
 
Crystallographic data:   Monoclinic; C2/c; a = 30.5163 (16) Å, b = 8.5881 (5) Å, c = 
21.0518 (12) Å; β = 101.0540 (10)°; V = 5414.8 (5) Å3; Z = 8; Dx = 1.758 g/cm3; R = 
0.033, wR(F2) = 0.090 
Selected geometric parameters:   Au-P = 2.2584 (9) Å;  Au – S = 2.3062 (9) Å; 
 S—C1= 1.752 (4); O—C1 = 1.356 (5) Å; N—C1 = 1.261 (5) Å; P1—Au—S1 = 178.02 
(4) Å. 
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Figure 62 Crystallographic structure of 2MePhNCSOMePh3PAu 
 
Crystallographic data:   Triclinic; P1; a = 8.1340 (6) Å, b = 13.8225 (11) Å, c = 13.8274 
(11) Å; β = 98.515 (2)°; V = 1296.92 (17) Å3; Z = 2; Dx = 1.676  g/cm3; R = 0.040, 
wR(F2) = 0.131 
Selected geometric parameters:   Au-P = 2.2559 (13) Å;  Au – S = 2.3008 (14) Å; 
 S—C1= 1.750 (6); O—C1 = 1.359 (7) Å; N—C1 = 1.259 (8) Å; P1—Au—S1 = 175.50 
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Figure 63 Crystallographic structure of 2MePhNCSOEtPh3PAu 
 
Crystallographic data:   Triclinic; P1; a = 9.3378 (6) Å, b = 10.1665 (6) Å, c = 13.9711 
(8) Å; β = 103.3710 (10)°; V = 1265.11 (13) Å3; Z = 2; Dx = 1.716 g/cm3; R = 0.034, 
wR(F2) = 0.108 
Selected geometric parameters:   Au-P = 2.2508 (10) Å;  Au – S = 2.3103 (10) Å; 
 S—C1= 1.767 (4); O—C1 = 1.361 (5) Å; N—C1 = 1.259 (6) Å; P1—Au—S1 = 176.99 
(4) Å. 
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Figure 64 Crystallographic structure of 3MePhNCSOMePh3PAu 
 
Crystallographic data: a = 10.4994 (7) Å, b = 10.7694 (7) Å, c = 12.7755 (8) Å; β = 
114.0680 (10)°; V = 1230.54 (14) Å3; Z = 2; Dx = 1.726 g/cm3; R = 0.040, wR(F2) = 
0.119 
Selected geometric parameters:   Au-P = 2.2472 (11) Å;  Au – S = 2.2976 (13) Å; 
 S—C1= 1.751 (5) Å; O—C1 = 1.358 (6) Å; N—C1 = 1.267 (6) Å; P1—Au—S1 = 
175.08 (4) Å. 
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Figure 65 Crystallographic structure of 2ClPhNCSOMeCy3PAu 
 
Crystallographic data: Triclinic; P1; a = 11.1028 (8) Å, b = 11.7525 (8) Å, c = 12.5356 
(9) Å; β = 98.1050 (10)°; V = 1399.81 (17) Å3; Z = 2; Dx = 1.609 g/cm3; R = 0.038, 
wR(F2) = 0.104 
Selected geometric parameters:   Au-P = 2.2631 (10) Å;  Au – S = 2.3082 (11) Å; S—




  Appendix 3  
Phosphinegold(I) Thiolates: Synthesis and Biological Activities 170  
 
Figure 66 Crystallographic structure of 2ClPhNCSOEtCy3PAu 
 
Crystallographic data:   Monoclinic; P21/n; a = 12.0513 (11) Å, b = 18.2460 (16) Å, c = 
13.9712 (12) Å; β = 108.892 (2)°; V = 2906.6 (4) Å3; Z = 4; Dx = 1.581 g/cm3; R = 
0.041, wR(F2) = 0.120 
Selected geometric parameters:   Au-P = 2.2655 (12) Å;  Au – S = 2.3066 (13) 
 Å; S—C1= 1.733 (6) Å; O—C1 = 1.364 (6) Å; N—C1 = 1.262 (7) Å; P1—Au—S1 = 
177.60 (5) Å. 
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Figure 67 Crystallographic structure of 2ClPhNCSOiPrCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 7.6552 (17) Å, b = 12.183 (3) Å, c = 17.595 (4) 
Å; β = 80.121 (4)°; V = 1496.4 (6) Å3; Z = 2; Dx = 1.567 g/cm3; R = 0.047, wR(F2) = 
0.134 
Selected geometric parameters:   Au-P = 2.2715 (15) Å;  Au – S = 2.2999 (15) Å; 
 S—C1= 1.742 (6) Å; O—C1 = 1.359 (7) Å; N—C1 = 1.272 (8) Å; P1—Au—S1 = 
175.74 (5) Å. 
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Figure 68 Crystallographic structure of 3ClPhNCSOMeCy3PAu 
 
Crystallographic data:  Monoclinic; P21/c; a = 19.1964 (8) Å, b = 11.7855 (5) Å, c = 
26.0594 (11) Å; β = 107.3280 (10)°; V = 5628.1 (4) Å3; Z = 8; Dx = 1.600 g/cm3; R = 
0.041, wR(F2) = 0.110 
Selected geometric parameters:   Au-P = 2.2566 (13) Å;  Au – S = 2.2983 (13) Å; 
 S—C1= 1.741 (5) Å; O—C1 = 1.356 (5) Å; N—C1 = 1.258 (6) Å; P1—Au—S1 = 
175.09 (4) Å.  
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Figure 69 Crystallographic structure of 3ClPhNCSOEtCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 7.6791 (5) Å, b = 13.3558 (10) Å, c = 14.6831 
(10) Å; β = 101.560 (2)°; V = 1430.91 (17) Å3; Z = 2; Dx = 1.606  g/cm3; R = 0.046, 
wR(F2) = 0.133 
Selected geometric parameters:   Au-P = 2.2707(15) Å;  Au – S = 2.2930 (16) Å; 
 S—C1= 1.756 (6) Å; O—C1 = 1.359 (7) Å; N—C1 = 1.270 (8) Å; P1—Au—S1 = 
176.44 (5) Å. 
 
 
  Appendix 3  
Phosphinegold(I) Thiolates: Synthesis and Biological Activities 174  
 
Figure 70 Crystallographic structure of 4ClPhNCSOMeCy3PAu 
 
Crystallographic data:   Monoclinic, P21; a = 7.7393 (7) Å, b = 16.7231 (14) Å, c = 
10.9873 (9) Å; β = 107.453 (2)°; V = 1356.6 (2) Å3; Z = 2; Dx = 1.660  g/cm3; R = 0.037, 
wR(F2) = 0.115 
Selected geometric parameters:   Au-P = 2.2663 (18) Å;  Au – S = 2.3132 (19) Å; 
 S—C1= 1.764 (10) Å; O—C1 = 1.309 (11) Å; N—C1 = 1.284 (9) Å; P1—Au—S1 = 
178.57 (8) Å. 
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Figure 71 Crystallographic structure of 4ClPhNCSOEtCy3PAu 
 
Crystallographic data:   Orthorhombic, Pna21; a = 22.135 (3) Å, b = 7.6508 (10) Å, c = 
16.597 (2) Å; β = 2810.7 (7)°; V = 2810.7 (7) Å3; Z = 4; Dx = 1.635 g/cm3; R = 0.067, 
wR(F2) = 0.146 
Selected geometric parameters:   Au-P = 2.269 (3) Å;  Au – S = 2.319 (3) Å; 
 S—C1= 1.732 (11) Å; O—C1 = 1.354 (12) Å; N—C1 = 1.289 (11) Å; P1—Au—S1 = 
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Figure 72 Crystallographic structure of 4ClPhNCSOiPrCy3PAu 
 
Crystallographic data:   Monoclinic, P21/c; a = 9.4547 (15) Å, b = 26.137 (4) Å, c = 
12.326 (2) Å; β = 100.162 (3)°; V = 2998.0 (8) Å3; Z = 4; Dx = 1.564 g/cm3; R = 0.047, 
wR(F2) = 0.102 
Selected geometric parameters:   Au-P = 2.2654 (12) Å;  Au – S = 2.3031 (13) Å; 
 S—C1= 1.747 (5) Å; O—C1 = 1.355 (5) Å; N—C1 = 1.262 (6) Å; P1—Au—S1 = 




  Appendix 3  
Phosphinegold(I) Thiolates: Synthesis and Biological Activities 177  
 
Figure 73 Crystallographic structure of 2MePhNCSOMeCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 9.7698 (6) Å, b = 12.1349 (8) Å, c = 24.5415 
(16) Å; β = 96.7050 (10)°; V = 2782.4 (3) Å3; Z = 4; Dx = 1.758 g/cm3; R = 0.047, 
wR(F2) = 0.152 
Selected geometric parameters:   Au-P = 2.2640 (16) Å;  Au – S = 2.2980 (19) Å; 
 S—C1= 1.750 (7) Å; O—C1 = 1.358 (8) Å; N—C1 = 1.262 (9) Å; P1—Au—S1 = 
171.60 (8) Å. 
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Figure 74 Crystallographic structure of 2MePhNCSOiPrCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 7.7188 (4) Å, b = 12.1174 (6) Å, c = 17.4778 
(8) (16) Å; β = 79.8120 (10)°; V = 1495.19 (13) Å3; Z = 4; Dx = 1.523 g/cm3; R = 0.039, 
wR(F2) = 0.097 
Selected geometric parameters:   Au-P = 2.2677 (10) Å;  Au – S = 2.2973 (10) Å; 
 S—C1= 1.757 (4) Å; O—C1 = 1.348 (5) Å; N—C1 = 1.268 (5) Å; P1—Au—S1 = 
175.66 (3) Å. 
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Figure 75 Crystallographic structure of 3MePhNCSOEtCy3PAu 
 
Crystallographic data:   Monoclinic; P21/c; a = 9.7602 (4) Å, b = 20.8176 (8) Å, c = 
14.1275 (5) Å; β = 93.4370 (10)°; V = 2865.32 (19) Å3; Z = 4; Dx = 1.557  g/cm3; R = 
0.033, wR(F2) = 0.090 
Selected geometric parameters:   Au-P = 2.2697 (7) Å;  Au – S = 2.3124 (7) Å; 
 S—C1= 1.762 (3) Å; O—C1 = 1.348 (3) Å; N—C1 = 1.267 (4) Å; P1—Au—S1 = 
178.63 (2) Å. 
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Figure 76 Crystallographic structure of 3MePhNCSOiPrCy3PAu 
 
Crystallographic data:   Monoclinic; P21/c; a = 13.7415 (18) Å, b = 13.3528 (18) Å, c = 
16.788 (2) Å; β = 100.308 (3)°; V = 3030.7 (7) Å3; Z = 4; Dx = 1.557  g/cm3; R = 0.033, 
wR(F2) = 0.079 
Selected geometric parameters:   Au-P = 2.2695 (8) Å;  Au – S = 2.3053 (9) Å; 
 S—C1= 1.765 (4) (9) Å; O—C1 = 1.365 (4) Å; N—C1 = 1.268 (5) Å; P1—Au—S1 = 
174.74 (3) Å. 
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Figure 77 Crystallographic structure of 4ClPhNCSOMeEt3PAu 
 
Crystallographic data:   Tetragonal, P4/n; a = 21.5192 (9) Å, b = 21.5192 (9) Å, c = 
7.7834 (5) Å; β = 90°; V = 3604.3 (3) Å3; Z = 8; Dx = 1.901 g/cm3; R = 0.036, wR(F2) = 
0.089 
Selected geometric parameters:   Au-P = 2.2584 (10) Å;  Au – S = 2.3156 (10) 
 Å; S—C1= 1.742 (5) Å; O—C1 = 1.370 (5) Å; N—C1 = 1.264 (5) Å; P1—Au—S1 = 
178.32 (4) Å.118 
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Figure 78 Crystallographic structure of nPrNCSOMePh3PAu 
 
Crystallographic data:   Monoclinic, P21/n; a = 13.9852 (16) Å, b = 11.1592 (13) Å, c = 
15.0975 (17) Å; β = 107.605 (2)°; V = 2245.8 (4) Å3; Z = 4; Dx = 1.749 g/cm3; R = 
0.051, wR(F2) = 0.124 
Selected geometric parameters:   Au-P = 2.2563 (15) Å;  Au – S = 2.3098 (15) Å; 
 S—C1= 1.772 (7) Å; O—C1 = 1.366 (8) Å; N—C1 = 1.265 (8) Å; P1—Au—S1 = 
176.71 (6) Å. 
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Figure 79 Crystallographic structure of nPrNCSOEtPh3PAu 
 
Crystallographic data:   Monoclinic, P21/n; a = 8.5822 (6) Å, b = 18.2036 (13) Å, c = 
15.6893 (12) Å; β = 102.001 (2)°; V = 2397.5 (3) Å3; Z = 4; Dx = 1.677 g/cm3; R = 
0.040, wR(F2) = 0.105 
Selected geometric parameters:   Au-P = 2.2567 (13) Å;  Au – S = 2.2983 (13) Å; 
 S—C1= 1.764 (6) Å; O—C1 = 1.352 (6) Å; N—C1 = 1.262 (8) Å; P1—Au—S1 = 
176.65 (5) Å. 
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Figure 80 Crystallographic structure of iPrNCSOEtPh3PAu 
 
Crystallographic data:   Triclinic; P1; a = 8.7105 (11) Å, b = 18.295 (2)  Å, c = 15.760 (2) 
Å; β = 104.707 (2)°; V = 2429.1 (5) Å3; Z = 8; Dx = 1.656 g/cm3; R = 0.039, wR(F2) = 
0.078 
Selected geometric parameters:   Au-P = 2.2569 (14) Å;  Au – S = 2.3030 (14) Å; 
 S—C1= 1.756 (6) Å; O—C1 = 1.371 (7) Å; N—C1 = 1.272 (7) Å; P1—Au—S1 = 
177.24 (6) Å. 
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Figure 81 Crystallographic structure of iPrNCSOEtCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 9.1226 (6) Å, b = 12.3857 (8) Å, c = 12.6754 
(9) Å; β = 105.380 (2)°; V = 1336.94 (16) Å3; Z = 8; Dx = 1.549 g/cm3; R = 0.037, 
wR(F2) = 0.112 
Selected geometric parameters:   Au-P = 2.2664 (11) Å;  Au – S = 2.3029 (12) Å; 
 S—C1= 1.750 (5) Å; O—C1 = 1.364 (6) Å; N—C1 = 1.257 (6) Å; P1—Au—S1 = 
173.42 (4) Å 
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Figure 82 Crystallographic structure of iPrNCSOiPrCy3PAu 
 
Crystallographic data:   Triclinic; P1; a = 11.1236 (5) Å, b = 11.7949 (6) Å, c = 11.9037 
(6) Å; β = 85.2820 (10)°; V = 1375.30 (12) Å3; Z = 2; Dx = 1.549 g/cm3; R = 0.024, 
wR(F2) = 0.059 
Selected geometric parameters:   Au-P = 2.2604 (6) Å;  Au – S = 2.3091 (7) Å; 
 S—C1= 1.767 (3) Å; O—C1 = 1.366 (3) Å; N—C1 = 1.263 (3) Å; P1—Au—S1 = 
174.94 (2) Å 
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1 L01 2ClPhNHCSOMe 201.67 3.25 3.25 21.22 55.34 3 248.53 
2 L02 2ClPhNHCSOEt 215.7 3.59 3.59 23.06 60.09 3 282.03 
3 L03 2ClPhNHCSOiPr 229.73 4.01 4.00 24.91 64.51 3 310.35 
4 L04 3ClPhNHCSOMe 201.67 3.25 3.25 21.21 55.34 3 248.73 
5 L05 3ClPhNHCSOEt 215.7 3.59 3.59 23.05 60.09 3 282.74 
6 L06 3ClPhNHCSOiPr 229.73 4.01 4.00 24.9 64.51 3 310.78 
7 L07 4ClPhNHCSOMe 201.67 3.25 3.25 21.21 55.34 3 249.36 
8 L08 4ClPhNHCSOEt 215.7 3.59 3.59 23.05 60.09 3 282.78 
9 L09 4ClPhNHCSOiPr 229.73 4.01 4.01 24.89 64.51 3 310.54 
10 L10 2MePhNHCSOMe 181.23 3.2 3.2 21.07 55.58 2 265.14 
11 L11 2MePhNHCSOEt 195.28 3.54 3.54 22.91 60.33 2 298.46 
12 L12 2MePhNHCSOiPr 209.31 3.95 3.95 24.76 64.74 2 326.84 
13 L13 3MePhNHCSOMe 181.23 3.2 3.2 21.07 55.58 2 265.31 
14 L14 3MePhNHCSOEt 195.28 3.54 3.54 22.91 60.33 2 298.62 
15 L15 3MePhNHCSOiPr 209.31 3.95 3.95 24.76 64.74 2 326.79 
16 L16 EtNHCSOMe 119.19 0.92 0.92 13.38 33.73 1 187.69 
17 L17 EtNHCSOEt 133.21 1.26 1.26 15.22 38.47 1 220.66 
18 L18 EtNHCSOiPr 147.24 1.67 1.67 17.06 42.89 1 250.01 
19 L19 nPrNHCSOMe 133.21 1.38 1.38 15.22 38.25 1 218.41 
20 L20 nPrNHCSOEt 147.24 1.73 1.73 17.06 43.00 1 251.64 
21 L21 nPrNHCSOiPr 161.27 2.14 2.14 18.91 47.42 1 280.74 
22 L22 iPrNHCSOMe 133.21 1.33 1.33 15.22 38.14 1 218.87 
23 L23 iPrNHCSOEt 147.24 1.67 1.67 17.06 42.89 1 250.96 
24 L24 iPrNHCSOiPr 161.27 2.08 2.08 18.91 47.31 1 280.48 
25 L25 4MePhNHCSOMe 181.23 3.2 3.2 21.07 55.58 2 264.92 
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No Label 
Thiocarbamate 












26 L26 4MePHNHCSOEt 195.28 3.54 3.54 22.91 60.33 2 297.99 
27 L27 4MePhNHCSOiPr 209.31 3.95 3.95 24.76 64.74 2 326.78 
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Table 19 Descriptors for phosphinegold(I) thiolates using Marvin Software calculator 
 













1 P01 2ClPhNCSOMePh3PAu 659.92 8.99 8.67 58.89 135.23 3 644.39 
2 P02 2ClPhNCSOEtPh3PAu 673.94 9.34 9.01 60.72 139.97 3 675.46 
3 P03 2ClPhNCSOiPrPh3PAu 687.97 9.75 9.42 62.55 144.39 3 704.75 
4 P04 3ClPhNCSOMePh3PAu 659.92 8.99 8.67 58.88 135.23 3 767.93 
5 P05 3ClPhNCSOEtPh3PAu 673.94 9.33 9.01 60.7 139.97 3 705.21 
6 P06 3ClPhNCSOiPrPh3PAu 687.97 9.75 9.42 62.53 144.39 3 705.49 
7 P07 4ClPhNCSOMePh3PAu 659.92 8.99 8.67 58.87 135.23 3 645.44 
8 P08 4ClPhNCSOEtPh3PAu 673.94 9.34 9.01 60.7 139.97 3 676.51 
9 P09 4ClPhNCSOiPrPh3PAu 687.97 9.75 9.42 62.53 144.39 3 704.88 
10 P10 2MePhNCSOMePh3PAu 639.5 8.94 8.62 58.64 135.46 2 659.96 
11 P11 2MePhNCSOEtPh3PAu 653.53 9.28 8.96 60.47 140.21 2 692.31 
12 P12 2MePhNCSOiPrPh3PAu 667.55 9.7 9.37 62.3 144.63 2 721 
13 P13 3MePhNCSOMePh3PAu 639.5 8.94 8.62 58.64 135.46 2 660.9 
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14 P14 3MePhNCSOEtPh3PAu 653.53 9.28 8.96 60.47 140.21 2 692.49 
15 P15 3MePhNCSOiPrPh3PAu 667.55 9.7 9.37 62.3 144.63 2 721.91 
16 P16 2ClPhNCSOMeCy3PAu 678.06 6.88 8.48 61.14 139.35 3 788.18 
17 P17 2ClPhNCSOEtCy3PAu 692.09 7.23 8.83 62.96 144.1 3 819.69 
18 P18 2ClPhNCSOiPrCy3PAu 706.11 7.64 9.24 64.78 148.52 3 847.61 
19 P19 3ClPhNCSOMeCy3PAu 678.06 6.88 8.48 61.12 139.35 3 786.26 
20 P20 3ClPhNCSOEtCy3PAu 692.09 7.23 8.83 62.95 144.1 3 820.72 
21 P21 3ClPhNCSOiPrCy3PAu 706.11 7.64 9.24 64.77 148.52 3 848.8 
22 P22 4ClPhNCSOMeCy3PAu 678.06 6.88 8.48 61.12 139.35 3 788.61 
23 P23 4ClPhNCSOEtCy3PAu 692.09 7.23 8.83 62.94 144.1 3 819.55 
24 P24 4ClPhNCSOiPrCy3PAu 706.11 7.64 9.24 64.77 148.52 3 848.98 
25 P25 2MePhNCSOMeCy3PAu 657.64 6.83 8.43 60.87 139.59 2 803.7 
26 P26 2MePhNCSOEtCy3PAu 671.67 7.18 8.77 62.7 144.33 2 834.51 
27 P27 2MePhNCSOiPrCy3PAu 685.7 7.59 9.19 64.53 148.75 2 863.95 
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28 P28 3MePhNCSOMeCy3PAu 657.64 6.83 8.43 60.87 139.59 2 804.46 
29 P29 3MePhNCSOEtCy3PAu 671.67 7.18 8.77 62.7 144.3 2 834.95 
30 P30 3MePhNCSOiPrCy3PAu 685.7 7.59 9.19 64.53 148.75 2 865.69 
31 P31 2ClPhNCSOMeEt3PAu 515.79 3.26 4.86 41.45 90.64 3 513.08 
32 P32 2ClPhNCSOEtEt3PAu 529.82 3.6 5.2 43.26 95.38 3 544.62 
33 P33 2ClPhNCSOiPrEt3PAu 543.84 4.02 5.62 45.07 99.8 3 573.48 
34 P34 3ClPhNCSOMeEt3PAu 515.79 3.26 4.86 41.44 90.64 3 514.24 
35 P35 3ClPhNCSOEtEt3PAu 529.82 3.6 5.2 43.24 95.38 3 545.16 
36 P36 3ClPhNCSOiPrEt3PAu 543.84 4.02 5.62 45.05 99.8 3 573.95 
37 P37 4ClPhNCSOMeEt3PAu 515.79 3.26 4.86 41.43 90.64 3 514.16 
38 P38 4ClPhNCSOEtEt3PAu 529.82 3.6 5.2 43.24 95.38 3 545.27 
39 P39 4ClPhNCSOiPrEt3PAu 543.84 4.02 5.62 45.05 99.8 3 574.01 
40 P40 2MePhNCSOMeEt3PAu 495.37 3.21 4.81 41.15 90.87 2 529.9 
41 P41 2MePhNCSOEtEt3PAu 509.4 3.55 5.15 42.96 95.62 2 561 
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42 P42 2MePhNCSOiPrEt3PAu 523.42 3.97 5.57 44.77 100.04 2 589.51 
43 P43 3MePhNCSOMeEt3PAu 495.37 3.21 4.81 41.15 90.87 2 530.26 
44 P44 3MePhNCSOEtEt3PAu 509.4 3.55 5.15 42.96 95.62 2 561.02 
45 P45 3MePhNCSOiPrEt3PAu 523.42 3.97 5.57 44.77 100.04 2 589.62 
46 P46 EtNCSOMePh3PAu 577.43 6.71 6.38 51.06 113.38 2 585.48 
47 P47 EtNCSOEtPh3PAu 591.46 7.05 6.73 52.88 118.13 2 617.39 
48 P48 EtNCSOiPrPh3PAu 605.48 7.47 7.14 54.71 122.54 2 645.96 
49 P49 nPrNCSOMePh3PAu 591.46 7.18 6.85 52.88 117.9 2 616.29 
50 P50 nPrNCSOEtPh3PAu 605.48 7.52 7.19 54.71 112.65 2 647.65 
51 P51 nPrNCSOiPrPh3PAu 619.51 7.93 7.61 56.54 122.07 2 677.01 
52 P52 iPrNCSOMePh3PAu 591.46 7.12 6.8 52.88 117.8 2 614.26 
53 P53 iPrNCSOEtPh3PAu 605.48 7.47 7.14 54.71 122.54 2 646.27 
54 P54 iPrNCSOiPrPh3PAu 619.51 7.88 7.55 56.54 126.96 2 675.07 
55 P55 EtNCSOMeCy3PAu 595.57 4.6 6.2 53.31 117.5 2 725.72 
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56 P56 EtNCSOEtCy3PAu 609.6 4.94 6.54 55.13 112.25 2 757.17 
57 P57 EtNCSOiPrCy3PAu 623.63 5.36 6.96 56.95 126.67 2 786.58 
58 P58 nPrNCSOMeCy3PAu 609.6 5.07 6.67 55.13 122.02 2 756.61 
59 P59 nPrNCSOEtCy3PAu 623.63 5.41 7.01 56.95 126.77 2 788.61 
60 P60 nPrNCSOiPrCy3PAu 637.65 5.82 7.42 58.78 131.19 2 816.6 
61 P61 iPrNCSOMeCy3PAu 609.6 5.01 6.61 55.13 121.92 2 754.66 
62 P62 iPrNCSOEtCy3PAu 623.63 5.36 6.95 56.95 126.67 2 786.93 
63 P63 iPrNCSOiPrCy3PAu 637.65 5.77 7.37 58.78 131.09 2 815.55 
64 P64 EtNCSOMeEt3PAu 433.3 0.98 2.58 33.66 68.79 2 453.34 
65 P65 EtNCSOEtEt3PAu 447.33 1.32 2.92 35.46 73.54 2 485.22 
66 P66 EtNCSOiPrEt3PAu 461.35 1.73 3.33 37.27 77.96 2 514.38 
67 P67 nPrNCSOMeEt3PAu 447.33 1.45 3.05 35.46 73.31 2 484.27 
68 P68 nPrNCSOEtEt3PAu 461.35 1.79 3.39 37.37 78.06 2 515.77 
69 P69 nPrNCSOiPrEt3PAu 475.38 2.2 3.8 39.07 82.48 2 545.14 
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70 P70 iPrNCSOMeEt3PAu 447.33 1.39 2.99 35.46 73.21 2 482.64 
71 P71 iPrNCSOEtEt3PAu 461.35 1.73 3.33 37.27 77.96 2 513.91 
72 P72 iPrNCSOiPrEt3PAu 475.38 2.15 3.75 39.07 82.37 2 542.6 
73 P73 4MePhNCSOMeEt3PAu 495.37 3.21 4.81 41.15 90.87 2 528.96 
74 P74 4MePhNCSOEtEt3PAu 509.4 3.55 5.15 42.96 95.62 2 560.86 
75 P75 4MePhNCSOiPrPh3PAu 667.55 9.7 9.37 62.3 144.63 2 721.95 
76 P76 4MePhNCSOEtCy3PAu 671.69 7.18 8.77 62.7 144.33 2 832.62 
77 P77 4MePhNCSOiPrEt3PAu 523.42 3.97 5.57 44.77 100.04 2 589.04 
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Table 20 The summary of R2 the correlation value of logP and biological 
activity of phosphinegold(I) thiolate on all cell lines at two concentrations. 
 






Table 21 The summary of R2 the correlation value of logD and biological 
activity of phosphinegold(I) thiolate on all cell lines at two concentrations. 
 






Table 22 The summary of R2 the correlation value of Polarisability and 







A498 0.0314 0.0257 
Hela 0.0034 0.0221 
HepG2 0.0322 0.0119 
HT29 0.0167 0.0952 
MCF7 0.0122 0.0098 
NCI 0.0905 0.0016 






A498 0.0335 0.0499 
Hela 0.0165 0.0198 
HepG2 0.0001 0.0136 
HT29 0.0003 0.0233 
MCF7 1.00E-06 0.0233 
NCI 0.0277 0.0015 






A498 0.0159 0.0468 
Hela 0.0151 0.0159 
HepG2 0.0123 0.0009 
HT29 0.0014 0.0084 
MCF7 0.0022 0.0046 
NCI 0.0461 0.0031 
OVCAR3 0.0056 0.0123 
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Table 23 The summary of R2 the correlation value of Polar surface area and 







A498 2.00E-16 5.00E-15 
Hela 5.00E-16 1.00E-14 
HepG2 7.00E-16 2.00E-14 
HT29 2.00E-16 1.00E-15 
MCF7 2.00E-16 6.00E-15 
NCI 1.00E-15 3.00E-14 
OVCAR3 2.00E-16 7.00E-15 
 
 
Table 24 The summary of R2 the correlation value of refractivity and biological 







Table 25 The summary of R2 the correlation value of LogP and biological 







A498 0.0056 0.2055 
Hela 0.1114 0.2268 
HepG2 0.0632 0.037 
HT29 0.1663 0.1227 
MCF7 0.0376 0.1115 
NCI 0.0066 0.006 







A498 0.0173 0.0314 
Hela 0.0078 0.0137 
HepG2 0.0213 0.0007 
HT29 0.0084 0.0607 
MCF7 0.0098 0.0038 
NCI 0.0614 0.0034 
OVCAR3 0.0159 0.0127 
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Table 26 The summary of R2 the correlation value of LogD and biological 







A498 0.0056 0.2055 
Hela 0.1114 0.2268 
HepG2 0.0632 0.037 
HT29 0.1663 0.1227 
MCF7 0.0376 0.1115 
NCI 0.0066 0.006 
OVCAR3 0.014 0.0069 
 
Table 27 The summary of R2 the correlation value of Polarisability and 







A498 0.0042 0.1721 
Hela 0.1203 0.1842 
HepG2 0.0743 0.0215 
HT29 0.1547 0.0928 
MCF7 4.67E-02 0.0833 
NCI 0.0057 0.0024 
OVCAR3 0.0133 0.0023 
 
 
Table 28 The summary of R2 the correlation value of polar surface area and 







A498 3.00E-15 3.00E-15 
Hela 6.00E-15 2.00E-15 
HepG2 4.00E-15 0 
HT29 3.00E-14 2.00E-14 
MCF7 7.00E-15 0 
NCI 8.00E-15 1.00E-15 
OVCAR3 1.00E-15 1.00E-14 
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Table 29 The summary of R2 the correlation value of polar surface area and 







A498 0.0038 0.1881 
Hela 0.116 0.2055 
HepG2 0.0668 0.0272 
HT29 0.1578 0.1127 
MCF7 3.93E-02 0.0956 
NCI 0.0059 0.0033 
OVCAR3 0.0109 0.0034 
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Figure 83 The correlation of descriptors and the biological activity of 





Figure 84 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on A498 cancer cell at low concentration 
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Figure 85 The correlation of descriptors and the biological activity of 







Figure 86 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on Hela cancer cell at low concentration 
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Figure 87 The correlation of descriptors and the biological activity of 





Figure 88 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on HepG2 cancer cell at low concentration 
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Figure 89 The correlation of descriptors and the biological activity of 





Figure 90 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on HT29 cancer cell at low concentration 
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Figure 91 The correlation of descriptors and the biological activity of 





Figure 92 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on MCF7 cancer cell at low concentration 
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Figure 93 The correlation of descriptors and the biological activity of 





Figure 94 The correlation of descriptors and the biological activity of 
Thiocarbamate ligands on NCI cancer cell at low concentration 
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Figure 95 The correlation of descriptors and the biological activity of 






Figure 96 The correlation of descriptors and the biological activity of 
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Figure 97 The correlation of descriptors and the biological activity of 







Figure 98 The correlation of descriptors and the biological activity of 
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SIMCA-P+ 11 - 13/10/2009 1:54:06 PM
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Figure 99 The correlation of descriptors and the biological activity of 




Figure 100 The correlation of descriptors and the biological activity of 
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Figure 101 The correlation of descriptors and the biological activity of 




Figure 102 The correlation of descriptors and the biological activity of 
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Figure 103 The correlation of descriptors and the biological activity of 




Figure 104 The correlation of descriptors and the biological activity of 
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Figure 105 The correlation of descriptors and the biological activity of 





Figure 106 The correlation of descriptors and the biological activity of 
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Figure 107 The correlation of descriptors and the biological activity of 




Figure 108 The correlation of descriptors and the biological activity of 
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Figure 109 The correlation of descriptors and the biological activity of 
Phosphinegold(I) Thiolates on OVCAR3 cancer cell at high concentration 
 
 
Figure 110 The correlation of descriptors and the biological activity of 
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